



# Thyroid Hormones

Jason Ryan, MD, MPH




# Thyroid Hormones

- Produced by the thyroid gland
- **Triiodothyronine (T<sub>3</sub>)** and **thyroxine (T<sub>4</sub>)**
- Both synthesized from tyrosine and iodine



Triiodothyronine (T<sub>3</sub>)




Thyroxine (T<sub>4</sub>)

# Thyroid Hormones

- Contain the element **iodine**
- **Iodized salt**
  - Table salt (NaCl) mixed with small minute amount of iodine
  - Done in many countries to prevent iodine deficiency
  - Added to salt in US in 1924
- For thyroid hormone, iodine in our diet needs to be:
  - Oxidized to  $I_2$  (“oxidation”)
  - Added to organic/carbon structures (“organification”)

		2 He
8 O	9 F	10 Ne
16 S	17 Cl	18 Ar
34 Se	35 Br	36 Kr
52 Te	53 I	54 Xe




# TPO

## Thyroid Peroxidase

- Multifunctional enzyme
- Catalyzes several steps in thyroid hormone synthesis
- Oxidation of iodine
- Organification of iodine into MIT/DIT
- Coupling of MIT/DIT into T3/T4
- **TPO antibodies** common in autoimmune thyroid disease

# Thyroid Peroxidase


TPO



**Tyrosine**

Organification

**TPO**





**Monoiodotyrosine (MIT)**

Organification


**Iodine (I<sub>2</sub>)**

**TPO**




**Diiodotyrosine (DIT)**

**TPO**




**Triiodothyronine (T<sub>3</sub>)**



**Thyroxine (T<sub>4</sub>)**


# Thyroglobulin

- Protein produced by thyroid follicular cells
- Contains numerous tyrosine molecules
- Tyrosine → MIT/DIT → T3/T4
- **Thyroglobulin antibodies** in autoimmune thyroid disease




# Thyroid Hormones

- Thyroxine ( $T_4$ ) is major hormone produced by thyroid gland
- Over 90% of thyroid hormone produced is  $T_4$
- Triiodothyronine ( $T_3$ ) more potent hormone
- **5' deiodinase** converts  $T_4 \rightarrow T_3$
- Most conversion occurs in **peripheral tissues**




# Wolff-Chaikoff Effect

- Excessive iodine in diet could lead to hyperthyroidism
- Thyroid protects itself via Wolff-Chaikoff Effect
- Iodine inhibits synthesis of thyroid hormone
  - Organification inhibited by  $\uparrow$  iodine
  - Less synthesis of MIT/DIT
- Normal patients “escape” with time




# Wolff-Chaikoff Effect

- “Failure to escape”
  - Iodine → prolonged ↓ hormone → hypothyroidism
  - Occurs in amiodarone-induced hypothyroidism
  - May also occur in autoimmune thyroid disease
- Jod-Basedow phenomenon
  - Lack of Wolff-Chaikoff effect
  - Excess iodine → hyperthyroidism
  - Occurs in patients with toxic adenomas



# Thyroid Hormone Regulation

- **Hypothalamus** releases **thyroid releasing hormone (TRH)**
- **Anterior pituitary** releases **thyrotropin (TSH)**
- Thyroid gland releases T3 and T4
- Feedback on pituitary and hypothalamus



# TBG

## Thyroxine-Binding Globulin

- Thyroid hormones poorly soluble in water
- Circulates bound to TBG (produced in liver)
- Most plasma thyroid hormone is T4
- Almost all T4 is bound to TBG
- Bound T4 does not exert hormone effects
- Small amount of “free T4” produces hormone effects

# Thyroid Panel

- Four standard measurements to assess thyroid


Test	Normal Value
TSH	0.5 to 5.0 mU/L
Total T4	60 to 145 nmol/L
Total T3	1.1 to 3 nmol/L
Free T4	0.01-0.03nmol/L

Note:  
T4 > T3  
Total T4 >> Free T4  
(most bound to TBG)

# TBG

## Thyroxine-Binding Globulin


- Increased production due to **estrogen**
  - Occurs in pregnancy
  - Contraceptives or hormone replacement
  - Raise total T4
  - TSH and free T4 will be normal
- Classic findings **high estrogen states**
  - Elevated total T4
  - Normal TSH and free T4
  - Does not indicate thyroid disease



# Thyroid Hormones

## Pregnancy

- Rise in TBG levels (estrogen)
- Rise in total T4 level
- hCG stimulates thyroid (same alpha unit as TSH)
- Raises free T4 → lower TSH




# Thyroid Hormone Effects

- Major regulator of **metabolic activity** and **growth**
- Glucose and lipid metabolism
- Cardiac function
- Bone growth
- CNS development

# Thyroid Hormone

## Metabolic Effects

- ↑ carbohydrate metabolism
  - ↑ glycogenolysis, gluconeogenesis
  - ↑ serum glucose
- ↑ lipid metabolism
  - ↓ concentrations of cholesterol, triglycerides
- Hypothyroid patients: **↑ cholesterol**
  - Check TSH in hyperlipidemic patients
- Hyperthyroid patients: **hyperglycemia**



# Thyroid Hormone

## Metabolic Effects

- ↑ basal metabolic rate
  - Basal rate of energy use per time
  - Amount of energy burned if you slept all day
- ↑ Na/K ATPase pumps
  - More pumps = more ATP consumed
  - ↑ oxygen demand to replenish ATP
  - ↑ respiratory rate
  - ↑ body temperature
- Hypothyroid patients: **weight gain**
- Hyperthyroid patients: **weight loss**



Wikipedia/Public Domain

# Thyroid Hormone

## Cardiac Effects

- $\uparrow$   $\beta_1$  receptors in heart
- $\uparrow$  cardiac output and heart rate
- Hypothyroid patients: **bradycardia**
- Hyperthyroid patients: **tachycardia or arrhythmias**

Tachycardia




# Thyroid Hormone

## Bone effects

- Thyroid hormones increase bone turnover
- Stimulates bone resorption
- Hyperthyroidism: **osteoporosis** and **hypercalcemia**


## Osteoporosis



# Thyroid Hormone

## CNS and Bone Development

- TH required for normal bone growth/CNS maturation
- Childhood hypothyroidism → **cretinism**
  - Stunted growth
  - Intellectual disability
  - Large tongue
  - Umbilical hernia
- Causes
  - Iodine deficiency
  - Congenital thyroid disease



Wellcome Images/Wikipedia

# Hypothyroidism

Jason Ryan, MD, MPH



# Hypothyroidism

- Underproduction of thyroid hormone by thyroid gland
- Metabolism **SLOWS DOWN**
- Highly variable clinical features
- Symptoms can be subtle
- Some patients have minimal symptoms



# Hypothyroidism

## Clinical Features

- Lethargy and fatigue
- Weakness
- Cold intolerance
- Weight gain with loss of appetite
- Constipation
- Hyporeflexia
- Dry, cool skin
- Coarse, brittle hair
- Bradycardia

Sinus Bradycardia




# Hypothyroidism

## Clinical Features

- Hyperlipidemia
  - ↑ total cholesterol
  - ↑ LDL cholesterol
  - TSH often checked in hyperlipidemia
- Myopathy
  - Muscle symptoms common in hypothyroid
  - Weakness, cramps, myalgias
  - ↑ serum **creatin kinase (CK)** common (up to 90%)
- Hyponatremia
  - High levels of ADH (SIADH)

**Structure of a Skeletal Muscle**



# Hypothyroidism

## Clinical Features

- Infertility
  - Associated with increased prolactin
  - Low FSH/LH
  - Disruption of menstrual cycle
  - Low sperm count
- Cognitive impairment
- Depression
- Hypertension
  - Causes aortic stiffness



# Myxedema

## Thyroid dermopathy

- **Non-pitting edema** of the skin from hypothyroidism
- Hyaluronic acid deposits in dermis
- Draws water out → swelling
- Usually facial/periorbital swelling
- Pretibial myxedema
  - Special form of myxedema over shin
  - Seen in Grave's disease (hyperthyroidism)
- Myxedema coma = coma from hypothyroidism



Herbert L. Fred, MD and Hendrik A. van Dijk

# Hypothyroidism

## Subtypes

- **Primary hypothyroidism**
  - Most common form
  - Failure of thyroid gland function due to disease or iodine deficiency
  - **TSH will be high**
- Central hypothyroidism: rare
  - Failure of pituitary gland or hypothalamus
  - Same causes as hypopituitarism
  - Usually occurs with deficiency of other pituitary hormones
  - Workup usually involves MRI of brain
  - **TSH will be low or inappropriately normal**



# Hypothyroidism

## Lab Findings

Test	Normal Value	Primary	Central
TSH	0.5 to 5.0 mU/L	HIGH	LOW or NL
Total T4	60 to 145 nmol/L	Low	Low
Total T3	1.1 to 3 nmol/L	Low	Low
Free T4	0.01-0.03nmol/L	Low	Low

# Goiter

- Enlarged thyroid
- Mild forms detected on physical exam
- Normal thyroid = 15 to 25 grams
- Caused by excess stimulation of thyroid gland
- **Primary hypothyroidism**
  - High TSH, inability to produce T3/T4
- **Hyperthyroidism** due to **Grave's disease**
  - Thyroid stimulating antibodies



Wikipedia/Public Domain

# Subclinical Hypothyroidism

- **Normal free T4**
- **Increased TSH**
- Generally asymptomatic
- Often identified on **routine lab work**
- Same causes as overt hypothyroidism
- Treated only if **TSH > 10 mU/L**
- High risk of and progression to symptoms
- Also risk of atherosclerosis and myocardial infarction

10

# Thyroid Function in Illness

## Euthyroid Sick Syndrome


- Thyroid hormone levels often abnormal in critically-ill patients
- Related to underlying illness with **no treatment required**
- Levels only checked if strong suspicion of thyroid disease
- **Low T3:** low conversion T4 → T3 (cortisol, cytokines)
- May also see **low TSH** → Low T3/T4
- Early: low T3; low-normal TSH and T4
- Late: Low TSH, T3 and T4



# Thyroid Function in Illness

## Euthyroid Sick Syndrome

- Key test: **reverse T3 (rT3)**
  - Isomer of T3
  - Level rises in critical illness due to impaired clearance
- Critically ill patient with low TSH/T4/T3
  - Check rT3
  - Low → central hypothyroidism
  - High → sick euthyroid syndrome (no treatment)



# Primary Hypothyroidism

## Causes, demographics and workup


- Most common cause worldwide: **iodine deficiency**
  - Rare in US due to iodized salt
- Most common cause US: **autoimmune thyroiditis**
- Prevalence increases with age
- More common in women
- Diagnosis by lab testing (TSH, T3, T4)
- Additional testing usually not performed
- Antibody testing or nuclear scans only used in select cases



# Primary Hypothyroidism

## Treatment

- **Levothyroxine**
- Synthetic T4
- Check TSH in 6 weeks
- Titrate dose to normal TSH (0.5 to 5.0 mU/L)
- Treat **all symptomatic patients**
- Subclinical patients: TSH concentrations  $>10$  mU/L



# Primary Hypothyroidism


## Treatment

- Higher dosages required with **higher TBG levels**
- Occurs in **high estrogen states**
- Pregnancy
- Hormone replacement therapy



# Myxedema Coma


- Severe hypothyroidism
- Altered mental status, **hypothermia** and organ dysfunction
- Hypoventilation, bradycardia
- Hyponatremia
- May be due to severe, longstanding hypothyroidism
- Or caused by an acute event in poorly-controlled hypothyroidism
  - Infection, myocardial infarction, surgery
  - Administration of sedatives (e.g., opioids)



# Myxedema Coma

## Diagnosis and Treatment

- Diagnosis: TSH and thyroid hormone levels
- Intravenous combined therapy: T4 (levothyroxine) and T3 (liothyronine)
- Stress-dose glucocorticoids
  - Often IV hydrocortisone 100 mg every eight hours
- Mechanical ventilation
- Intravenous fluids



Hydrocortisone

# Primary Hypothyroidism

## Causes

- Chronic lymphocytic thyroiditis
- Other forms of thyroiditis
- Iodine deficiency
- Drugs

# Thyroiditis


- Thyroid gland inflammation
- Painful when caused by infection, radiation or trauma
- Painless when caused by autoimmune disease or medications
- May initially cause hyperthyroidism → hypothyroidism
- Most common form: chronic lymphocytic thyroiditis

# Chronic Lymphocytic Thyroiditis

## Hashimoto's Thyroiditis

- Most common cause of hypothyroidism in the US
- Infiltration of thyroid gland by lymphocytes
  - Autoimmune disorder
  - HLA-DR3, HLA-DR5 and others
- Antibodies produced
  - Anti-TPO
  - Anti-thyroglobulin
  - Not required to begin treatment
  - Can be used to confirm the diagnosis

Lymphocyte



# Chronic Lymphocytic Thyroiditis

## Hashimoto's Thyroiditis

- Primarily occurs in older women
- Enlarged non-tender thyroid gland
- Gradual loss of thyroid function → symptoms
- Symptoms and labs consistent with hypothyroidism
- Treatment: thyroid hormone replacement
- Increased risk of **non-Hodgkin B cell lymphoma**




Dr. Ryan's Grandmother

# Subacute Thyroiditis

## de Quervain's Thyroiditis/Granulomatous Thyroiditis

- Post-viral inflammation of thyroid
- Most common cause of thyroid pain
- Occurs in young women
- Tender, enlarged thyroid gland
- Variable lab findings
- Hyperthyroid → euthyroid → hypothyroid
- Thyroid symptoms usually mild (no treatment)
- Elevated ESR and CRP




# Subacute Thyroiditis

## de Quervain's Thyroiditis/Granulomatous Thyroiditis

- Clinical diagnosis
  - Neck pain with tender, enlarged thyroid
- Low thyroid radioiodine uptake
  - Usually less than 1 to 3 percent
  - Inflammation interferes with uptake
- Treatment:
  - Anti-inflammatories (aspirin, NSAIDs, steroids)
  - Usually resolves in few weeks

Radioactive Iodine Uptake Scan



# Subacute Lymphocytic Thyroiditis

## Painless Thyroiditis

- Variant of Hashimoto's
- Lymphocytic infiltration of thyroid gland
- Transient mild hyperthyroidism
- Resembles Grave's disease without eye/skin findings
- Serum thyroid stimulating immunoglobulins not elevated
- Radioiodine uptake low when hyperthyroid
  - Contrast with Grave's disease: upper normal or high
- Rarely can be followed by hypothyroidism
- Usually self-limited – resolves over weeks

# Postpartum Thyroiditis

- Similar to painless thyroiditis
- By definition occurs within one year after pregnancy
- Delivery of baby or after spontaneous/induced abortion
- Self-limited



# Fibrous Thyroiditis

## Riedel's Thyroiditis

- Fibroblast activation and proliferation
- Fibrous tissue (collagen) deposition in thyroid
- “Rock hard” thyroid
- Often extends beyond the thyroid
  - Parathyroid glands → hypoparathyroidism
  - Recurrent laryngeal nerves → hoarseness
  - Trachea compression → difficulty breathing




# Fibrous Thyroiditis

## Riedel's Thyroiditis

- Associated with **IgG4 plasma cells**
  - IgG4 plasma cells identified in biopsy specimens
- Diagnosis: biopsy
- Treatment: thyroid hormone replacement
- Surgery often required to relieve thoracic compression


Plasma Cell



# Infiltrative Thyroid Disease

- Fibrous thyroiditis
- Amyloidosis
- Sarcoidosis
- Hereditary hemochromatosis

Amyloidosis



# Iodine Deficiency

- Constant elevation of TSH → enlarged thyroid
- “Endemic goiter”
- Goiter in regions with widespread iodine deficiency




# Goitrogens

- Substances that inhibit thyroid hormone production
- **Lithium** (inhibits release of thyroid hormone)
- Amiodarone

1 H			
3 Li	4 Be		
11 Na	12 Mg		
19 K	20 Ca	21 Sc	22 Ti
37 Rb	38 Sr	39 Y	40 Zr

# Amiodarone

- Antiarrhythmic drug
- May cause **hypothyroidism**
  - Excess iodine → Wolff-Chaikoff Effect
  - Normal patients “escape” in few weeks
  - Pre-existing subclinical thyroid disease → “failure to escape”
  - Also inhibits conversion of T4 → T3
- May also cause **hyperthyroidism**
  - Increased iodine → increase hormone synthesis
  - May also cause thyroiditis → hyperthyroidism
- Must check **TSH** prior to starting therapy



Amiodarone

# Iatrogenic Hypothyroidism

- Thyroid surgery
  - Treatment for Grave's or malignancy
- Radioiodine therapy
  - I<sup>131</sup> administered orally as solution or capsule
  - Beta-emissions → tissue damage
  - Ablation of thyroid function over weeks
  - Treatment for Grave's or malignancy
- Neck radiation
  - Hodgkin's lymphoma
  - Head and neck cancer



# Hyperthyroidism

Jason Ryan, MD, MPH



# Hyperthyroidism

- Overproduction of thyroid hormone by thyroid gland
- Metabolism **SPEEDS UP**
- Hyperactivity
- Heat intolerance
- Weight loss with increased appetite
- Diarrhea
- Hyperreflexia
- Warm, moist skin
- Fine hair
- Tachycardia (atrial fibrillation)



# Hyperthyroidism

## Subtypes

- **Primary hyperthyroidism**
  - Most common form
  - Overactivity of thyroid gland not due to high TSH
  - Low TSH with high T3/T4
- Central hyperthyroidism: rare
  - Excess TSH from pituitary gland
  - High TSH and high T3/T4
  - **Neoplastic: pituitary tumor (TSHoma)**
  - Non-neoplastic: pituitary resistance to thyroid hormone



# Hyperthyroidism

## Lab Findings

Test	Normal Value	Primary	Central
TSH	0.5 to 5.0 mU/L	LOW	NL or HIGH
Total T4	60 to 145 nmol/L	High	High
Total T3	1.1 to 3 nmol/L	High	High
Free T4	0.01-0.03nmol/L	High	High

# Primary Hyperthyroidism

## Causes

- Grave's disease (most common)
- Multinodular goiter
- Toxic adenoma
- Iodine-induced
- Amiodarone
- Thyroiditis
- Levothyroxine

# Grave's Disease

- Autoimmune disease
- Thyroid stimulating antibodies produced
- Symptoms of hyperthyroidism occur
- Large non-nodular thyroid



# Grave's Disease

## Special features

- **Exophthalmos (bulging eyes)**
  - Proptosis (protrusion of eye) and periorbital edema
  - Retroocular fibroblast and adipocyte activation
- **Pretibial myxedema (shins)**
  - Fibroblasts contain TSH receptor
  - Stimulation → secretion of glycosaminoglycans
  - Draws in water → swelling



Jonathan Trobe, M.D./Wikipedia




Herbert L. Fred, MD and Hendrik A. van Dijk

# Grave's Disease

## Diagnosis

- Often clinical: hyperthyroid symptoms and labs, goiter plus exophthalmos
- **TSH receptor antibodies**
  - Thyrotropin receptor antibodies (TRAb)
  - Also called TSIs: “Thyroid stimulating immunoglobulins”
- **Radioactive iodine uptake**
  - Increased due to overactive thyroid

Radioactive Iodine Uptake Scan



# Grave's Disease

## Treatment

- Symptom control: **beta blockers**
  - Used for initial treatment of symptoms
  - Improves tachycardia
  - Usually atenolol – once daily dosing
- Decrease thyroid hormone synthesis
  - Thionamides
  - Radioiodine thyroid ablation
  - Surgery



# Thionamides

- Inhibit production of thyroid hormone
- Used initially to improve moderate to severe symptoms
- **Methimazole**
  - Most commonly used drug
  - Once daily dosing - usually well tolerated
- **Propylthiouracil**
  - Main use is 1<sup>st</sup> trimester of pregnancy
  - Lower risk of adverse fetal effects
  - Also used in thyroid storm




# Thionamides

## Adverse Effects

- **Agranulocytosis**
  - Rare drop in WBC
  - May present as fever, infection after starting drug
  - WBC improves with stopping drug
  - Aplastic anemia cases reported
- Hepatotoxicity
- Baseline testing: **CBC and LFTs**
- Monitoring WBC: controversial
  - Not recommended by American Thyroid Association guidelines
  - Most clinicians advise patients to report any signs of infection
  - Signs of infection → stop drug → check CBC

Agranulocytosis



# Grave's Disease

## Treatment

- **Radioiodine ablation**
  - Usually given as oral capsule
  - Concentrated in thyroid → ablation
  - Requires lifelong replacement therapy
  - Associated with increase in TRAb
  - May lead to **worsening orbitopathy**
- **Surgery (thyroidectomy)**
  - May cause hypoparathyroidism
  - May cause recurrent laryngeal nerve damage
  - Associated with a fall in TRAb
  - Does not worsen orbitopathy




# Thyroidectomy

## Post-operative hypocalcemia

- Common complications of thyroidectomy
- Paresthesias of lips, mouth, hands and feet
- Muscle twitches or cramps
- Rarely trismus (lockjaw) or tetany
- Reduced serum calcium
- Treatment: **IV calcium gluconate**

1 H	
3 Li	4 Be
11 Na	12 Mg
19 K	20 Ca



# Grave's Orbitopathy


- Can cause irritation, excessive tearing or eye pain
- Symptoms often worsened by cold air, wind or bright lights
- Immune-mediated process
- Mainstay of treatment when severe: **glucocorticoids**
- Other immunosuppressants may be used
- Also treated with radiation or surgery



# Toxic Adenomas

- **Thyroid nodules**
  - Function independently
  - Usually contain mutated TSH receptor
  - No response to TSH
  - One nodule: toxic adenoma
  - Multiple: toxic multinodular goiter
- Findings:
  - Palpable nodule(s) or nodular goiter
  - Hyperthyroidism symptoms/labs
  - Increased uptake of radioiodine in nodule(s)

Multinodular Goiter



# Toxic Adenomas

## Treatment

- Initial symptom control: beta blockers and thionamides
- Preferred therapy for most patients: **radioiodine ablation**
  - Accumulates in hyperfunctioning nodules
  - Underactive surrounding tissue not affected
  - Patient may become euthyroid and avoid thyroid replacement
- Surgery in select patients
  - Large, obstructive goiters
  - Coexisting thyroid malignancy



# Iodine-Induced Hyperthyroidism

## Jod-Basedow Phenomenon

- Wolff-Chaikoff effect: excess iodine → decreased hormone production
- Some patients “escape” the Wolff-Chaikoff effect
- Called the Jod-Basedow Phenomenon
- Excess iodine → hyperthyroidism

		2 He
8 O	9 F	10 Ne
16 S	17 Cl	18 Ar
34 Se	35 Br	36 Kr
52 Te	53 I	54 Xe

# Iodine-Induced Hyperthyroidism

## Jod-Basedow Phenomenon

- Often occurs in regions of **iodine deficiency**
  - Introduction of iodine → hyperthyroidism
- Often occurs in patients with **toxic adenomas**
  - Drugs administered with high iodine content
  - Expectorants (potassium iodide), CT contrast dye
  - Amiodarone


		2 He
8 O	9 F	10 Ne
16 S	17 Cl	18 Ar
34 Se	35 Br	36 Kr
52 Te	53 I	54 Xe

# Amiodarone

## Hyperthyroidism

- Type I
  - Occurs in patients with **pre-existing thyroid disease**
  - Grave's or Multi-nodular goiter
  - Amiodarone provides iodine → excess hormone production
  - Increased radioiodine uptake
- Type II
  - Destructive thyroiditis
  - Excess release T4/ T3 (no ↑ hormone synthesis)
  - Direct toxic effect of drug
  - Can occur in patients **without pre-existing thyroid illness**
  - Decreased radioiodine uptake


Amiodarone



# Amiodarone

## Hyperthyroidism Management


- Stop amiodarone if possible
- Radioiodine uptake test to distinguish type I from type II
- Type I: beta blockers, thionamides, ablation or surgery
- Type II (thyroiditis): **glucocorticoids**



# Hyperthyroidism


## Other Causes

- **Early thyroiditis**
  - Low radioiodine uptake
  - High serum thyroglobulin concentration
- **Exogenous hyperthyroidism**
  - Excess levothyroxine
  - Supplements with thyroid hormone
  - Low radioiodine uptake
  - Low serum thyroglobulin concentration



# Hyperthyroidism

## Workup



# Thyroid Storm


- Life-threatening hyperthyroidism
- Usually precipitated by **acute event**
  - Patient with pre-existing hyperthyroid disease
  - Grave's or toxic multinodular goiter
  - Surgery, trauma, infection
- Massive catecholamine surge
- Acute increase in thyroid hormone levels



# Thyroid Storm

## Clinical Features



- Fever (up to 106<sup>0</sup>F)
- Delirium
- Tachycardia with possible death from arrhythmia
- Warm skin
- **Tremor**
- Hyperglycemia (catecholamines/thyroid hormone)
- Hypercalcemia (bone turnover)
- Diagnosis: increased free T4 and T3; low TSH



# Thyroid Storm

## Treatment

- **Propranolol**
  - Beta blocker → improves symptoms
  - Also blocks T4 → T3 conversion
- **Propylthiouracil**
  - Preferred over methimazole
  - Decreases T4 → T3 conversion
- **Glucocorticoids**
  - Decreases T4 → T3 conversion
  - Reduces inflammation if Graves' disease present



# Thyroid Storm

## Treatment

- **Iodine**
  - Potassium iodide-iodine (Lugol's) solution
  - Blocks release of T4 and T3 from thyroid gland
- ICU level care



# Thyroid Nodules

Jason Ryan, MD, MPH



# Thyroid Nodules


- Identified by patients or detected on physical exam by clinician
- Incidental finding on imaging
  - Carotid ultrasound
  - Neck or chest CT
- May have benign cause
  - Cyst, adenoma
- Major clinical concern: **thyroid cancer**
  - Cause of about 5 to 10% nodules



# Thyroid Nodules

## Workup


- TSH
- Thyroid ultrasound
- Radioactive iodine uptake scan
- Fine needle aspiration



# Thyroid Nodules

## TSH Measurement

- **Low TSH**
  - Overt or subclinical hyperthyroidism
  - Suggests hyperfunctioning nodule
  - Also T3/T4 measurement for hyperthyroidism
  - Risk of malignancy low
- **Normal or high TSH**
  - Possibly malignant nodule
  - Higher TSH = higher likelihood cancer



# Thyroid Nodules

## Radioactive iodine scan


- **Hyperfunctioning (“hot”) nodule**
  - Greater uptake than surrounding tissue
  - Evaluate for hyperthyroidism
  - Risk of malignancy low
  - FNA not required
- **Nonfunctioning (“cold”) nodule**
  - Less uptake than surrounding tissue
  - Follow-up testing with ultrasound
  - May require FNA



Normal



Cold Nodule




Hot Nodule

# Thyroid Nodules


## Thyroid Ultrasound

- Purely cystic lesions are almost always benign
- Suspicious lesions followed by FNA
  - Large nodules ( $\geq 2$  cm)
  - Micro calcifications
  - Irregular margins
  - Extrathyroidal invasion



# Thyroid Nodules

## Workup



# Thyroid Nodules

## Fine Needle Aspiration

- Usually performed under **US guidance**
- Six categories of results based on Bethesda classification system

Class	Description	Follow-up
I	Non-diagnostic	Repeat FNA
II	Benign	Reassurance and periodic US follow-up
III	Atypia of undetermined significance	Variable
IV	Suspicious for follicular neoplasm	Variable
V	Suspicious for malignancy	Surgery
VI	Malignant	Surgery


# Thyroid Cancer

- Papillary
- Follicular
- Medullary
- Anaplastic
- Lymphoma

# Papillary Carcinoma

- Most common form thyroid cancer (~ 80%)
- Increased risk with **prior radiation exposure**
  - Childhood chest radiation for mediastinal malignancy
  - Survivors of atomic bomb detonation (Japan)
  - Nuclear power plant accidents (Chernobyl)
- Median age at diagnosis is 51 years
- Presents as thyroid nodule
- Sometimes identified on imaging (CT/MRI)
- Diagnosis made after fine needle aspiration (FNA)

Papillary Carcinoma



# Papillary Carcinoma


- Excellent prognosis
- Treated with **surgery**
  - Total thyroidectomy or lobectomy
  - Based on size and degree of spread
- Post-operative T4 (levothyroxine)
  - Prevent hypothyroidism
  - Prevent TSH rise → cancer growth
- Radioactive iodine ablation
  - Based on patient risk category
  - Ablate residual normal thyroid tissue
  - Eliminate metastatic cells



# Follicular Carcinoma

- Malignancy of follicular epithelial cells
- Similar to follicular adenoma
- Breaks through (“invades”) fibrous capsule
- FNA cannot distinguish between adenomas/cancer
- Many similarities with papillary carcinoma
  - Similar age and risk factors
  - Treatment similar to papillary carcinoma
  - Thyroidectomy
  - Radioiodine ablation of remaining tissue or metastasis


Follicular Carcinoma



# Medullary Carcinoma

- Cancer of parafollicular cells (C cells)
- Produces **calcitonin**
  - Lowers serum calcium
  - Normally minimal effect on calcium levels
  - Used for monitoring
- Amyloid protein deposits in thyroid
- Treatment: **total thyroidectomy**
  - Most patients have bilateral disease
- Serial calcitonin monitoring


Medullary Carcinoma



# MEN Syndromes

## Multiple Endocrine Neoplasia

- Gene mutations that run in families
- Cause multiple endocrine tumors
- MEN 2A and 2B associated with medullary carcinoma
  - Caused by RET oncogene mutation
  - Some patients have **elective thyroidectomy**
  - Sometimes at a young age




# Anaplastic Carcinoma

## Undifferentiated Carcinoma

- Occurs in **elderly**
- Highly malignant - invades local tissues
  - Dysphagia (esophagus)
  - Hoarseness (recurrent laryngeal nerve)
  - Dyspnea (trachea)
  - Don't confuse with Riedel's ("rock hard" thyroid/young pt)
- Poor prognosis
- Treatment: surgery (local disease only), chemotherapy and radiation

# Primary Thyroid Lymphoma

- Rare B-cell lymphoma arising in thyroid gland
- Associated with **chronic lymphocytic thyroiditis (Hashimoto's)**




# Hyperaldosteronism

Jason Ryan, MD, MPH




# Primary Hyperaldosteronism

- Excessive levels of aldosterone secretion
- Not due to increased activity of RAAS
- Adrenal adenoma (Conn's syndrome)
- Bilateral idiopathic adrenal hyperplasia
- Rarely adrenal carcinoma (~1%)



# Primary Hyperaldosteronism

- ↑ Na reabsorption distal nephron
- ↑ circulating volume → **hypertension**
- ↑ K excretion → **hypokalemia**
- ↑ H<sup>+</sup> excretion → metabolic alkalosis
  - High serum bicarbonate



# Aldosterone Escape

- Excess aldosterone does not lead to volume overload
- Usually no pitting edema, rales, increased JVP
- Na and water retention → hypertension
- Compensatory mechanisms activated
- Increased ANP
- Increased sodium and free water excretion
- Result: diuresis → **normal volume status**



# Primary Hyperaldosteronism

## Clinical Features

- **Resistant hypertension**
- Possible hypokalemia
  - Inconsistent finding
  - Less than 30% in some studies
- Normal volume status on physical exam



# Primary Hyperaldosteronism

## Diagnosis

- Renin-independent aldosterone secretion
- **Plasma renin activity (PRA)**
  - Low in primary hyperaldosteronism
  - Usually than 1 ng/mL per hour
- **Plasma aldosterone concentration (PAC)**
  - High in primary hyperaldosteronism
  - Greater than 15 ng/dL
- **Ratio of PAC:PRA**
  - Greater than 20 suggest primary hyperaldosteronism

# Primary Hyperaldosteronism


## Confirmatory Testing

- Demonstration of inappropriate aldosterone secretion
- **Oral sodium load or sodium infusion**
- Should suppress aldosterone release
- Measure urinary aldosterone excretion or plasma aldosterone concentration
- Increased aldosterone after sodium load = positive test

# Primary Hyperaldosteronism

## Determination of cause

- **Abdominal CT scan**
  - Adrenal mass
  - Bilateral adrenal enlargement
- **Adrenal vein sampling**
  - Interventional radiology procedure
  - Separate blood sample from each vein
  - Measurement of aldosterone in samples
  - Distinguishes unilateral from bilateral disease




Metastatic adenocarcinoma within a functioning adrenal adenoma: A case report - Scientific Figure on ResearchGate.  
[https://www.researchgate.net/figure/Abdominal-CT-scan-arrow-depicts-right-adrenal-mass\\_fig5\\_38012436](https://www.researchgate.net/figure/Abdominal-CT-scan-arrow-depicts-right-adrenal-mass_fig5_38012436) [accessed 21 Jan, 2021]


# Primary Hyperaldosteronism

## Treatment

- Unilateral disease: **surgical adrenalectomy**
- Bilateral disease: **medical therapy**
- Drugs of choice: **spironolactone/eplerenone**
  - Aldosterone antagonists
- ACE inhibitors and ARBs: no effect
  - All levels already very low (↓ RAAS activity)
  - Aldosterone release not dependent on AII stimulation



Spironolactone




Eplerenone

# SAME

## Syndrome of Apparent Mineralocorticoid Excess

- Cortisol binds to renal aldosterone receptors
- Cortisol → cortisone by renal cells
- Enzyme: **11- $\beta$ -hydroxysteroid dehydrogenase**
- SAME: deficiency 11- $\beta$ -hydroxysteroid dehydrogenase
- Cortisol produces **aldosterone effects**



# SAME

## Syndrome of Apparent Mineralocorticoid Excess

- Presents in children/adolescents
- Similar clinical syndrome to hyperaldosteronism
  - Hypertension
  - Hypokalemia
  - Metabolic alkalosis
- **Low plasma renin activity**
- **Low plasma aldosterone levels**
- Treatment: potassium-sparing diuretics
  - Amiloride, spironolactone
  - Inhibit mineralocorticoid effects


# Licorice

- Contains **glycyrrhetic acid** (a steroid)
  - Weak mineralocorticoid effect
  - Inhibits renal 11-beta-hydroxysteroid dehydrogenase
- Large amounts may cause disease
- Hypertension, hypokalemia, metabolic alkalosis
- Low plasma renin activity
- Low plasma aldosterone levels



# Secondary Hyperaldosteronism

- Hyperreninemic hyperaldosteronism
- **Elevated plasma renin activity**
- Limited renal perfusion
- Renal artery stenosis
- Heart failure
- Cirrhosis
- Renin-secreting tumor (rare)



# Cushing's Syndrome


Jason Ryan, MD, MPH




# Cushing's Syndrome

## Hypercortisolism

- Clinical syndrome of **excess effects of cortisol**
- Cortisol: steroid hormone
- “Glucocorticoid:” raises serum glucose
- Synthesized by adrenal glands




Cortisol



# Pituitary-Adrenal Axis


- Controls **cortisol secretion**
- Hypothalamus: CRH
  - Corticotropin releasing hormone
  - Acts of pituitary gland
- Anterior pituitary: ACTH
  - Adrenocorticotropic hormone
  - Acts on adrenal gland
- Adrenal: cortisol



# Excess Cortisol

## Major Effects

- Immunosuppression
- Hyperglycemia
- Hypertension
- Fat deposition
- Muscle, bone and skin changes
- Reproductive effects




Cortisol

# Cortisol

## Immunosuppressive Effects


- **Reduces T and B cell levels in plasma**
  - Sequesters lymphocytes in spleen/nodes
- **Impairs neutrophils**
  - Blocks neutrophil migration
  - Increases peripheral neutrophil count
  - **Raises the white blood cell count**
- Mast cells: blocks histamine release
- Reduces eosinophil counts
- Basis for corticosteroids as immunosuppressive therapy

Neutrophils




# Corticosteroid Drugs


“Steroids” or “Glucocorticoids”




**Cortisol**




**Dexamethasone**




**Prednisone**




**Cortisone**




**Hydrocortisone**



**Triamcinolone**



**Betamethasone**




**Methylprednisolone**

# Cortisol

## Glucose Effects

- Increases liver **gluconeogenesis**
- More glucose produced by liver
- May cause insulin resistance
- **Increases serum glucose**
- Cortisol excess: hyperglycemia
- May worsen diabetes



# Cortisol

## Blood Pressure Effects

- Maintains **blood pressure**
- Modifies vascular smooth muscle tone
- ↑ cortisol: hypertension (Cushing's syndrome)
- ↓ cortisol: hypotension (adrenal insufficiency)



# Cortisol

## Lipid Effects

- Activation of lipolysis in adipocytes
- Can increase total cholesterol and triglycerides
- Stimulate adipocyte growth
- Key effect: **fat deposition**
  - Face (“Moon face”)
  - Trunk
  - Upper back (“Buffalo hump”)



# Cortisol

## Muscle, Skin and Bone Effects

- Muscle atrophy
  - Thin arms and legs
- **Thin skin**
- **Easy bruising**
- **Striae**
- **Osteopenia and osteoporosis**
  - Inhibits osteoblasts


Striae



# Cortisol

## Reproductive Effects


- Suppresses GnRH release → ↓ LH and FSH
- Hypogonadotropic hypogonadism
- Women: **irregular menses**
- Men: low testosterone



# Cushing's Syndrome

## Common Clinical Features

- Weight gain
- Hypertension
- Hyperglycemia
- Round face
- Menstrual irregularities
- Thin skin
- Bruising and striae



# Cushing's Syndrome

## Special Clinical Features

- **Skin hyperpigmentation**
- Only occurs in **ACTH-dependent** Cushing's syndrome
- Caused by **↑ ACTH** not cortisol
- **↑ ACTH** → **↑ MSH**
- Also seen in adrenal insufficiency
  - Loss of cortisol → **↑ ACTH**



# Cushing's Syndrome

## Special Clinical Features

- **Androgen excess**
- Occurs in some adrenal carcinomas
- Tumor secretes cortisol and androgens
- May cause **acne**
- Women: **hirsutism**

Hirsutism



# Cushing's Syndrome

## Causes

- Most common cause: **exogenous glucocorticoids**
  - Commonly oral prednisone
  - Administered for immunosuppressive effects
  - Many indications
- Rare causes:
  - Overproduction of ACTH by pituitary (Cushing's disease)
  - Ectopic ACTH syndrome (tumor)
  - Adrenal adenoma



# Cushing's Syndrome

## Causes

- **ACTH-dependent**
  - High ACTH level → hypercortisolism
  - Cushing's disease
  - Ectopic ACTH syndrome
- **ACTH-independent**
  - Low ACTH level
  - Adrenal adenoma

# ACTH

# Cushing's Syndrome

## Workup

- Step 1: exclude exogenous glucocorticoids
- Step 2: **diagnosis of hypercortisolism**
  - Twenty-four-hour urinary cortisol excretion
  - Late-night salivary cortisol
  - Late-night serum cortisol
  - Low-dose dexamethasone suppression test
  - If clinical suspicion high, sometimes 2 tests done (false negatives)
- Step 3: plasma ACTH

# Cushing's Syndrome

## Low dose dexamethasone suppression test

- Screening test for hypercortisolism
- 1mg dexamethasone (“low dose”) administered at bedtime
- Suppresses normal pituitary ACTH release
- Morning blood test → cortisol level should be low (suppressed)
- Cushing's syndrome: **cortisol will be high**
  - ACTH production not suppressed from pituitary adenomas or ectopic tumors
  - Cortisol production not suppressed from adrenal adenomas

# Cushing's Syndrome

## Plasma ACTH

- **Low plasma ACTH concentration**
  - ACTH-independent disease
  - Suggests adrenal tumor
  - Next best test: CT scan of adrenal glands
- **Normal or high ACTH concentration**
  - ACTH-dependent disease
  - Pituitary tumor or ectopic production
  - Next best test: determine source of ACTH production
  - High dose dexamethasone test
  - CRH stimulation test
  - Petrosal vein sampling

# ACTH

# Cushing's Syndrome

Source of ACTH production

- **High dose dexamethasone test (8mg)**
- Differentiates causes of high ACTH Cushing's syndrome
- Will suppress cortisol in pituitary adenomas
- Will not suppress cortisol from ACTH tumors

AM Cortisol After Dexamethasone

	Low Dose	High Dose
Normal	↓	↓
Pituitary Adenoma	--	↓
ACTH Tumor	--	--

# Cushing's Syndrome

Source of ACTH production

- **CRH stimulation test**
- Pituitary tumor: ACTH and cortisol increases after CRH administration
  - Pituitary cells actively synthesizing ACTH
  - Release can be increased by surge of CRH
- Ectopic tumors: no response
  - Pituitary cells NOT synthesizing ACTH
  - Pituitary cells inactive
  - Minimal or no response to surge in CRH


# Cushing's Syndrome

Source of ACTH production

- **Petrosal venous sampling**
- Petrosal venous sinus drains pituitary gland
- Venous blood sample obtained via catheter
- Gradient of central to peripheral ACTH measured
- Pituitary ACTH source: **high central-to-peripheral ACTH gradient**

# Cushing's Syndrome


## Workup



# Cushing's Disease

## Pituitary ACTH Release


- Usually caused by benign pituitary adenomas
- Usually microadenomas (< 10 mm in diameter)
- May be too small to identify by MRI
- Treatment: **transsphenoidal surgery**
- Main complication: diabetes insipidus (rarely permanent)
- Radiation if surgery unsuccessful



# Cushing's Syndrome

## Ectopic ACTH Release


- **Small cell lung cancer**
- Carcinoid tumors of lung
- Islet cell tumors of pancreas
- Medullary thyroid carcinoma
- Thymus gland tumors
- Treatment: surgical resection of tumor



# Cushing's Syndrome

## Adrenal Adenoma Treatment

- **Unilateral adrenalectomy**
- Refractory disease (any cause): bilateral adrenalectomy
  - Lifelong glucocorticoid and mineralocorticoid replacement




# Cushing's Disease

## ACTH Medical Treatments

- Used if surgery unsuccessful or not possible
- **Cabergoline**
  - Dopamine agonist
  - Used to treat hyperprolactinemia
  - Also suppresses ACTH release
- **Pasireotide**
  - Somatostatin analogue
  - Blocks the release of ACTH

Cabergoline




# Adrenal Insufficiency

Jason Ryan, MD, MPH



# Adrenal Insufficiency

- Loss of adrenal function
- Loss of one or more adrenal hormones
- Glucocorticoids: cortisol
- Mineralocorticoids: aldosterone
- Androgens: dehydroepiandrosterone (DHEA)



# Adrenal Insufficiency

## Types


- **Primary adrenal insufficiency**
  - “Addison’s disease”
  - Destruction of adrenal gland tissue
  - Loss of cortisol, aldosterone and androgens
- **Secondary or tertiary (central)**
  - Loss of ACTH from pituitary (secondary)
  - Loss of CRH from hypothalamus (tertiary)
  - Loss of cortisol only



# Glucocorticoid Deficiency

## Clinical Features

- Fatigue
- Weight loss
- **Gastrointestinal symptoms**
  - Usually nausea
  - Sometimes vomiting, abdominal pain or diarrhea
- Hypotension +/- syncope
  - Cortisol maintains vascular tone
  - Often orthostatic hypotension
- Muscle and joint pain
- Hyponatremia (↑ ADH release)




Cortisol


# Mineralocorticoid Deficiency

## Clinical Features

- **Hypovolemia**
  - “Salt wasting” – patient may crave salty foods
  - Loss of sodium and water in urine
  - May lead to hypovolemic shock
- Hyponatremia
  - High ADH from hypovolemia
  - Retention of free water
- Hyperkalemia
  - Decreased urinary potassium
- Metabolic acidosis
  - Decreased urinary acid excretion




Aldosterone



# Androgen Deficiency

## Clinical Features

- No significant impact in males (testes)
- Decreased axillary and pubic hair in females




Dehydroepiandrosterone  
(DHEA)

# Primary Adrenal Insufficiency

## Clinical Presentation

- Fatigue
- Weight loss
- Nausea, vomiting and abdominal pain
- Muscle and joint pain
- Postural hypotension
- Salt craving
- Hyponatremia
- Hyperkalemia
- Eosinophilia

Eosinophil



# Primary Adrenal Insufficiency

## Skin Hyperpigmentation

- ACTH is high in primary adrenal insufficiency
- ↑ melanocyte stimulating hormone (MSH)
- Common precursor in pituitary with ACTH
- Proopiomelanocortin (POMC)
- ↑ ACTH → ↑ MSH → ↑ melanin synthesis
- Most obvious in sun-exposed areas
  - Face, neck, backs of hands
- May also occur on mucous membranes



# Primary Adrenal Insufficiency

## Diagnosis

- **Morning cortisol**
  - Cortisol concentration higher in early morning
  - Low value at this time suggests adrenal insufficiency
- **Plasma ACTH**
  - Low cortisol + high ACTH = primary disease
  - Low cortisol + low ACTH = central disease
- **Cosyntropin stimulation test**
  - Used to quickly exclude adrenal insufficiency



# Cosyntropin Stimulation Test

- Cosyntropin: synthetic ACTH
- Standard high-dose test: 250 mcg
- Normal response: **rise in serum cortisol**
  - Measured after 30 or 60 minutes
  - Should peak at  $\geq 18$  to 20 mcg/dL
  - Normal response **rules out primary adrenal insufficiency**
  - Rules out most forms of central adrenal insufficiency
- Abnormal response = adrenal insufficiency
  - Primary disease: blunted rise due to adrenal pathology
  - Central disease: blunted rise due to adrenal atrophy

# Primary Adrenal Insufficiency

## Causes

- Autoimmune adrenalitis
  - Suggested by other autoimmune disorders
- Infectious adrenalitis
  - Tuberculosis, HIV
  - Disseminated fungal infections
- Hemorrhagic infarction
  - Associated with meningococemia
  - Waterhouse-Friderichsen syndrome
  - Increased risk with anticoagulant use
- Metastatic cancer

Neisseria Meningitis



# Primary Adrenal Insufficiency

## Determination of cause

- Cause may be evident from history and exam
  - Tuberculosis, HIV or meningococemia
- Antibodies against 21-hydroxylase
  - Autoimmune adrenalitis
- CT abdomen
  - Infection, hemorrhage or malignancy
- CT-directed fine needle aspiration
  - Infection or malignancy


CT Abdomen



# Primary Adrenal Insufficiency

## Treatment

- **Corticosteroids**
  - Dexamethasone, prednisone or hydrocortisone
- **Mineralocorticoids**
  - Fludrocortisone




Fludricortisone

# Central Adrenal Insufficiency

## Clinical Features

- Weakness and fatigue
- Muscle and joint pain
- Hypotension (less prominent)
  - Decreased vascular tone only
  - No loss of mineralocorticoids
- Hyponatremia (but less common)
  - Intact mineralocorticoids
  - Low cortisol  $\rightarrow$   $\uparrow$  ADH
- No skin hyperpigmentation (low ACTH)
- Diagnostic testing consistent with central disease

## Hypothalamus and Pituitary Gland




# Central Adrenal Insufficiency

## Evaluation and Treatment


- **Head MRI**
- CRH stimulation test
  - Differentiates 2° from 3°
  - No cortisol rise after CRH: 2° (pituitary failure)
  - Cortisol rise after CRH: 3° (hypothalamic failure)
- Treatment: glucocorticoids

Head MRI



# Adrenal Insufficiency


## Workup



# Central Adrenal Insufficiency

## Patients on Chronic Glucocorticoids


- Suppression of HPA axis
- ↓ CRH and ↓ ACTH
- Adrenal atrophy
  - Impaired ability to produce cortisol
  - Cortisol effects entirely from endogenous drugs
  - Mineralocorticoids intact from RAAS
- Patient dependent on endogenous glucocorticoids
- Cessation or underdosing → deficiency state



# Central Adrenal Insufficiency

## Patients on Chronic Glucocorticoids

- Longer duration therapy requires **tapering of dose** (“weaning”)
- Various regimens to prevent symptoms of adrenal insufficiency
- Usually a small decrease in dose every one to two weeks
- Suppression of HPA axis unlikely if treatment **under three weeks**



# Adrenal Crisis

- Acute-onset, life-threatening condition
- **Shock** due to sudden loss of adrenal hormones
- Poorly-responsive to fluids alone
- Resolves with glucocorticoid administration
- Consider in any hypotensive patient



# Adrenal Crisis

## Causes

- Occurs with **underlying adrenal disease** and **acute stressor**
  - Chronic primary adrenal insufficiency (possible initial presentation)
  - Chronic glucocorticoid therapy and adrenal atrophy
  - Adrenal function unable to increase in response to stressor
  - Stressors: trauma, surgery or major illness
- Also occurs with acute-onset adrenal gland destruction
  - Bilateral hemorrhage



# Adrenal Crisis

## Treatment and Prevention

- **“Stress dose steroids”**
  - Hydrocortisone intravenous bolus
  - Regular intravenous doses every few hours or infusion
- Prevention: stress dose steroids in patients on **chronic glucocorticoids**
  - High daily dose for more than 3 weeks
  - Prior to major surgery
  - After trauma
  - During major illness
- Not necessary for minor surgical procedures or low daily doses

# Diabetes Mellitus

Jason Ryan, MD, MPH



# Diabetes Mellitus

- Chronic disorder of **elevated blood glucose levels**
- Lack of insulin or poor response to insulin (“insulin resistance”)
- Can lead to symptoms of hyperglycemia
- Many **long-term complications**
  - Vascular disease
  - Kidney disease
  - Blindness



# Diabetes Mellitus

## Symptoms

- May be asymptomatic
  - “Silent killer”
  - No symptoms until complications develop
  - Basis for screening
- Classic hyperglycemia symptoms
  - **Polyuria** (osmotic diuresis from glucose)
  - **Polydipsia** (thirst to replace lost fluids)
  - Can present with diabetic ketoacidosis



# Diabetes Mellitus

## Diagnosis

- Symptomatic (polyuria, polydipsia, DKA)
  - Symptoms plus glucose  $\geq 200$  mg/dl = diabetes
- Asymptomatic
  - Fasting blood glucose level (no food for 8 hours)
  - Hemoglobin A1c  $> 6.5\%$
  - Two-hour plasma glucose  $\geq 200$  mg/dL after 75 g oral glucose tolerance test

State	Fasting plasma glucose
Normal	$< 100$ mg/dl
Pre-diabetes	100 to 125 mg/dl
Diabetes	$\geq 126$ mg/dl

# Diabetes Mellitus

## Stress hyperglycemia


- Occurs in normal individuals without diabetes
- Infection, trauma, surgery, burns
- Cortisol, epinephrine
- Does not indicate diabetes
- Diagnosis not usually done during in illness/stress



# Hemoglobin A1C

- Small fraction of hemoglobin is “glycated”
  - Glucose combines with alpha/beta chains
- Amount of HbA1c measured in diabetes
- Reflects average glucose **over past 3 months**
  - Normal < 5.7%
  - Pre-diabetes: 5.7 to 6.4%
  - Diabetes:  $\geq 6.5\%$
- Used for diagnosis and monitoring therapy

Hemoglobin



# Hemoglobin A1C

## Treatment Goals

- Lower value = better control of blood sugar
- Type I diabetes: < 7.0%
- Type II diabetes: < 7.0% for average adult patient
- Higher goal (< 8.0%) for older patients
  - Avoid hypoglycemia
  - Limited life expectancy for complications



# Glucose Tolerance Test

- Oral glucose load administered
- Plasma glucose measured 1-3 hours later
- High glucose indicates diabetes
- Often used to screen for **gestational diabetes**
  - Some insulin resistance normal in pregnancy
  - Fasting glucose and A1c not reliable
  - Need to study response to glucose load for diagnosis



# Type 1 Diabetes

- **Autoimmune disorder**
- Type IV hypersensitivity reaction
- Immune-mediated destruction of beta cells
- **Loss of insulin**
- Multifactorial etiology
- Genetics, environment
- Only major risk factor: family history



# Type 1 Diabetes

- Mostly a **childhood disorder**
  - Bimodal distribution
  - Peak at 4-6 years
  - 2<sup>nd</sup> peak 10 to 14 years of age
- Presents with **hyperglycemia symptoms**
  - Polyuria
  - Polydipsia
  - Glucose in urine
  - Diabetic ketoacidosis



# Type 1 Diabetes


## Diagnosis and treatment

- No standard screening
- Diagnosis usually made when symptoms occur
- Treatment: **insulin**



# Type 2 Diabetes

- Complex disorder of **insulin resistance**
- Reduced response to insulin → hyperglycemia
- Pancreas initially responds with ↑ insulin
- Eventually pancreas can fail → ↓ insulin
- Most common form of diabetes
- Common in **adults**
- Also becoming more common among children



# Type 2 Diabetes

## Risk Factors

- Major risk factor: **obesity**
  - Central or abdominal obesity carries greatest risk
  - Weight loss improves glucose levels
- Family history
  - Strong genetic component (more than type I)
  - Any first degree relative with T2DM: ↑ 2-3x risk
- Sedentary lifestyle
- Smoking



# Type 2 Diabetes

## Screening

- Guidelines vary slightly by expert groups
- American Diabetes Association
  - Screening for most patients **beginning age 45**
  - Earlier screening in high-risk groups
  - Repeat screening every 3 years
- US Preventive Services Task Force
  - Patients **40 to 70 who are overweight or obese**
  - Repeat screening every 3 years



# Type I versus Type II

## Diagnosis

- Usually distinguished by **clinical features**
- **Type I:**
  - Childhood onset
  - Rapid onset with severe hyperglycemia
  - Obesity less likely (~ 20%)
- **Type II:**
  - Puberty or adulthood
  - Often insidious onset (screening, polyuria/polydipsia)
  - Family history more likely
  - Obesity common (~ 80%)
- Islet-specific pancreatic autoantibodies in some cases of type I (not reliable)



# Type 2 Diabetes

## Management

- All patients: **maintain healthy weight and exercise**
  - Can be done prior to medical therapy in select cases
  - For *highly motivated patients* with A1C near target
  - Usually 3- to 6-month trial of lifestyle modification
- Most common initial therapy: **metformin**
- May add additional agents to achieve target A1c
- After failure of two or more agents consider insulin
- If severely elevated A1c ( $> 9.5\%$ ) consider insulin



# Bariatric Surgery

- Indicated for obese patients with type II diabetes
- Long-term remission up to 60% in some studies
- Reduced risk of diabetes complications
- Indicated for any patient with diabetes and BMI > 35
- Or 30 to 34.9 if hyperglycemia inadequately controlled



# Acanthosis Nigricans

- Hyperpigmented plaques on skin
- Intertriginous sites (folds)
- Classically neck and axillae
- Associated with **insulin resistance**
  - Often seen in obesity, diabetes
  - Much more common **type II**
- Rarely associated with malignancy
  - Gastric adenocarcinoma most common



# Diabetes Complications


Jason Ryan, MD, MPH



# Diabetes Mellitus

## Complications

- Chronic hyperglycemia → complications
- Vascular disease
- Kidney disease
- Neuropathy
- Ocular disease (blindness)




# Diabetic Macroangiopathy

## Atherosclerosis

- Coronary artery disease
  - Most common cause of death in diabetes
- Stroke and TIA
- Peripheral vascular disease

### Narrowing of Artery




Lipid deposit of  
plaque

# Diabetic Macroangiopathy

## Atherosclerosis

- **Screening lipid panel**
  - At time of diagnosis
  - At least every five years thereafter
- **Statin therapy**
  - US Preventive Services Task Force guidelines
  - **Diabetes + age  $\geq 40$  + 10-year risk  $> 10\%$**
  - Regardless of LDL level
- Routine EKG, stress test, imaging not indicated

## Narrowing of Artery




Lipid deposit of  
plaque

# Diabetic Kidney Disease

## Diabetic Microangiopathy


- Damage to glomeruli and arterioles
  - Efferent arteriole glycosylation
  - Hyperfiltration
  - Basement membrane damage
  - Mesangial and glomeruli sclerosis
- Causes **albuminuria**
- May lead to **end-stage kidney disease**



# Diabetic Kidney Disease

## Screening and Prevention

- **Annual urine albumin-to-creatinine ratio**
  - Measurement correlated to 24-hour urine values (mg/day)
  - Normal rate: less than 30 mg/day
  - Above 30 mg/day indicates diabetic nephropathy
- **ACE inhibitors and ARBs**
  - Indicated for albuminuria
  - Even if blood pressure is not elevated
  - Shown to reduce progression to ESRD
  - Slows progression of nephropathy
- **Hypertension goal: < 130/80 mmHg**



# Diabetic Peripheral Neuropathy


- Most common form of diabetic neuropathy
- “Distal symmetric polyneuropathy”
- “Stocking-glove” sensory loss
- Progressive loss of sensation: distal → proximal
- Severe cases: motor weakness

	<b>Large Myelinated Fibers</b>	<b>Small Myelinated Fibers</b>
Function	Proprioception/Pressure	Pain
Symptoms	Numbness, loss of balance	Burning, electric shocks
Exam Findings	Reduced ankle reflexes Reduced vibration Reduced proprioception	Loss of pinprick Loss of hot/cold discrimination

# Diabetic Peripheral Neuropathy

## Foot Ulcers

- Common problem in diabetes
- Loss of sensation → tissue damage
- Vascular disease → impaired healing
- May be painless
- Patients should check feet daily
- Annual foot exam and sensory testing
  - Monofilament testing (pressure)
  - Vibratory testing
  - Pinprick testing
  - Ankle reflexes



# Diabetic Peripheral Neuropathy


## Management

- Generally not reversible
- Glucose control slows progression
- Pain in feet (burning or stabbing)
  - SNRIs: duloxetine or venlafaxine
  - TCAs: amitriptyline, desipramine or nortriptyline
  - AEDs: pregabalin or gabapentin




# Diabetic Autonomic Neuropathy

- Abnormal function of autonomic nerves
- GU system: bladder dysfunction, erectile dysfunction
- GI: gastroparesis
- CV: orthostatic hypotension, silent ischemia



# Diabetic Eye Disease

- Cataracts
- Glaucoma
- Diabetic retinopathy
- Diabetic macular edema
- Annual screening for prevention
- Dilated fundus examination by trained specialist
- Usually ophthalmologist or optometrist




Petr Novák, Wikipedia

# Diabetic Eye Disease

## Cataracts

- Increased risk with diabetes
- Sorbitol accumulates in lens
- Increased osmolarity
- Fluid into lens
- Opacification over time



# Diabetic Eye Disease

## Retinopathy

- Can cause blindness
- **Nonproliferative retinopathy**
  - Microaneurysms or hemorrhages
  - Exudates: leakage of proteins and lipids
  - Cotton-wool spots (nerve infarctions)
- **Proliferative retinopathy**
  - Retinal ischemia → new vessel growth
  - “Neovascularization”
  - Treated with photocoagulation (laser)
  - Also intraocular anti-VEGF agents

Cotton Wool Spots



# Diabetes Mellitus

## Benefits of lowering blood glucose

- Several large, randomized trials of **intensive glycemic control**
  - Comparisons of lower versus higher A1c targets
- Type 2 diabetes
  - Lower risk of **microvascular complications**
  - Mostly retinopathy and nephropathy
  - Little impact on macrovascular disease (MI, stroke)
  - ACCORD trial: A1c 6.0 to 6.5% → increased mortality
- Type 1 diabetes
  - Lower risk of most complications
  - Microvascular and macrovascular

# Diabetic Ketoacidosis


Jason Ryan, MD, MPH



# Diabetic Ketoacidosis

## DKA

- Life-threatening complication of diabetes
- Biochemical derangement: hyperglycemia, acidosis
- Requires **very low insulin effects**
- More common in **type 1**
- Common type 1 initial presentation
- Often precipitated by infection or trauma ( $\uparrow$  epinephrine)
- Can occur with missed insulin dose in type 1 diabetes ( $\downarrow$  insulin)



# Diabetic Ketoacidosis

## DKA


- ↑ epinephrine or ↓ insulin → increased glucose
- Very low insulin effects → liver ketone synthesis
- Net result: **hyperglycemia** + **ketones**
- Osmotic diuresis (glucose) → **volume depletion**
- High ketones = **anion gap metabolic acidosis**
- Acidosis → **hyperkalemia**

Hyperglycemia  
Low bicarbonate  
Hyperkalemia  
Volume depletion

# Diabetic Ketoacidosis

## Clinical Presentation

- Abdominal pain, nausea and vomiting
- Volume depletion
  - Dry mucous membranes
  - Low blood pressure
- Hyperglycemia
- Low bicarbonate
- Hyperkalemia




# Diabetic Ketoacidosis

## Clinical Presentation

- Elevated plasma and urine ketones
- Glucose in urine
- Anion gap metabolic acidosis (↓ bicarbonate)
  - Kussmaul breathing: deep, labored breathing
  - Hyperventilation to blow off CO<sub>2</sub> and raise pH
- Fruity smell on breath (acetone)


Metabolic Acidosis  
Bicarbonate



# Diabetic Ketoacidosis

## Phosphate

- Risk of **hypophosphatemia**
  - Phosphaturia caused by osmotic diuresis
- Loss of ATP
  - Muscle weakness (respiratory failure)
  - Heart failure (↓ contractility)





Phosphate

# Diabetic Ketoacidosis

## Other features

- Arrhythmias (hyperkalemia)
- **Cerebral edema**
  - Mechanism poorly understood
  - Common cause of death in children with DKA



# Diabetic Ketoacidosis

## Diagnostic Criteria

- Triad: hyperglycemia, anion gap acidosis and ketones

Measurement	Criteria
Glucose	> 250 mg/dL
Arterial pH	< 7.30
Bicarbonate	< 18 mEq/L
Urine ketones	Positive
Serum ketones	Positive

# Diabetic Ketoacidosis

## Treatment


- **IV Fluids**
  - Volume replacement
  - Usually normal saline
  - Usually infused continuously
- **IV Insulin**
  - Lowers blood glucose levels
  - Inhibits liver production of ketones
  - Shifts potassium into cells
  - Bolus plus continuous drip



# Diabetic Ketoacidosis

## Treatment - Potassium


- Total body potassium is **low** from loss of potassium in urine
- Hyperkalemia presents initially due to acidosis/low insulin
  - Potassium **shifted out of cells** into plasma
- Hypokalemia may develop from insulin infusion
- Add potassium to IV fluids when potassium **less than 5.3 mEq/L**
  - Normal potassium: 3.6 to 5.2 mEq/L



# Diabetic Ketoacidosis

## Treatment – other electrolytes

- Monitor magnesium, calcium and phosphate
- Levels may fall due to loss in urine
- Replete as needed



Phosphate

# Diabetic Ketoacidosis

Treatment - bicarbonate infusion

- Usually not necessary
- Arterial pH will increase with DKA treatment
- Only indicated with  $\text{pH} \leq 6.9$  (impaired cardiac function)



# Diabetic Ketoacidosis

## Treatment monitoring


- Close monitoring of serum glucose and electrolytes
- When glucose approaches 200 mg/dL add **5% dextrose** to saline infusion
  - Allows continued insulin infusion to suppress ketones
  - Avoids hypoglycemia
  - Can also decrease insulin infusion rate
- DKA resolves when:
  - **Anion gap normalizes (less than 12 mEq/L)**
  - Beta-hydroxybutyrate absent (if available)
  - Patient can eat



# HHS

## Hyperglycemic Hyperosmolar Syndrome

- Life-threatening complication of diabetes
- More common in type 2
- Markedly elevated glucose (can be >1000)
- High glucose → diuresis and volume depletion
- High osmolarity → CNS dysfunction
- Usually no acidosis




# HHS

## Hyperglycemic Hyperosmolar Syndrome

- Very high serum osmolarity → CNS dysfunction
  - Caused by very high glucose (can be > 1000)
  - Normal plasma osmolarity: less than 300 mOsm/kg
  - HHS: usually above 320 mOsm/kg
- Few or no ketone bodies (insulin present)
  - Usually no acidosis
  - Different from DKA

$$\text{Serum Osmolarity} = 2 * [\text{Na}] + \frac{\text{Glucose}}{18} + \frac{\text{BUN}}{2.8}$$

### PLASMA OSMOLARITY



# HHS

## Clinical features and diagnosis

- Polyuria, polydipsia
- Volume depletion
- Mental status changes
- Confusion, even coma
- Diagnosis: serum glucose



# HHS

## Treatment

- Similar to DKA
- Insulin, fluids
- Resolved when:
  - Plasma osmolality below 315 mOsmol/kg
  - Patients alert and able to eat

**Resolved**

# Insulin

Jason Ryan, MD, MPH




# Type 1 and Type 2

- Type 1 diabetes treated mainly with **insulin**
- Type 2 diabetes: **oral or SQ drugs +/- insulin**
  - Initial stages: oral and/or SQ drugs
  - Advanced disease: insulin




# Insulin

- Many different types available for diabetes therapy
- All vary by **time to peak** and **duration of action**
- Also vary by peak effect



# Insulin Hexamers


- Insulin forms **hexamers** in the body
  - Six insulin molecules linked together
  - Stable structure
- Insulin usually administered **subcutaneously**
- Activity related to speed of absorption
- Insulin hexamers → slower onset of action
- Insulin monomers → faster onset of action



# Rapid-acting Insulin


Lispro, Aspart, and Glulisine

- Modified human insulin
- Insulin with modified amino acids
- Reduced hexamer/polymer formation
- Rapid absorption, fast action, short duration
  - Onset: 15 minutes
  - Peak: 1 hour
  - Duration: 2 to 4 hours
- Often used **pre-meal**




# Insulin

Rapid



# Regular Insulin

- Synthetic analog of **human insulin**
- Made by recombinant DNA techniques
- Onset: 30 minutes
- Peak: 2 to 4 hours
- Duration: 3 to 6 hours



# Regular Insulin


- Only type of insulin that is given IV
- IV regular insulin used in **DKA/HHS**
- Used to treat **hyperkalemia**
  - Given IV with glucose to prevent hypoglycemia



# NPH Insulin

## Neutral Protamine Hagedorn


- Regular insulin combined with **neutral protamine**
- Slows absorption
- Peak: ~ 8 hours
- Duration: 12-16 hours



# Basal insulin analogs

Glargine, Detemir, Degludec


- Insulin with modified chemical structure
- Provide **low, continuous** insulin effects
  - Onset: ~ 2 hours
  - Duration: up to 24 hours or more
  - Glargine and Detemir: up to 24 hours
  - Degludec: > 40 hours
- Often given **once daily**



# Insulin

## Administration

- Subcutaneous (SQ)
- Continuous infusion
  - Infusion pump
  - Rapid-acting insulin




# Hypoglycemia

- Major adverse effect of all insulin regimens
  - Tremor, palpitations, sweating, anxiety
  - If severe: seizure, coma
  - **Always check blood sugar in unconscious patients**
- Dosages, frequency adjusted to avoid low glucose



# Weight Gain

- Occurs in most patients on insulin
- Insulin promotes **fatty acid and protein synthesis**



Wikipedia/Public Domain

# Insulin

## Hypersensitivity Reactions

- **Immediate**

- IgE-mediated type I hypersensitivity reactions
- Occur within 1 hour of injection
- Local skin reactions: erythema, wheals, pruritus
- Systemic reactions: generalized urticaria and angioedema
- Treatment: antihistamines, glucocorticoids; epinephrine if anaphylaxis

- **Delayed**

- More than one hour after injection
- Induration and nodules at injection sites
- Contact dermatitis
- Treatment: topical corticosteroids

# Insulin

## Subcutaneous fat changes

- Lipohypertrophy: swelling of fatty tissue at injection sites
  - Insulin alters fatty tissue growth
- Lipoatrophy: loss of fatty tissue
- Prevention: **rotate injection sites**

Lipohypertrophy



Lipoatrophy



# Diabetes Treatment

Jason Ryan, MD, MPH



# Type 1 and Type 2 Treatment

- Type 1 diabetes treated mainly with **insulin**
- Type 2 diabetes: **oral or SQ drugs +/- insulin**
  - Most common initial therapy: **metformin**
  - Advanced disease: insulin



# Hemoglobin A1C

## Treatment Goals

- Type I diabetes: < 7.0%
- Type II diabetes: < 7.0% for average adult patient
  - Higher goal (< 8.0%) for older patients
- Lower value = lower average blood glucose levels
- Reduced risk of diabetes complications
  - Type I: most complications
  - Type II: microvascular complications
  - Especially **retinopathy and nephropathy**
  - May not reduce risk of macrovascular complications



# Antidiabetic Agents


Oral or Subcutaneous

- Biguanides (Metformin)
- Sulfonylureas
- Glitazones
- Glucosidase Inhibitors
- GLP-1 Analogs
- DPP-4 Inhibitors
- SGLT2 inhibitors

# Metformin

## Biguanide

- Oral medication
- Exact mechanism unknown
- Multiple metabolic effects
- **↓ hepatic glucose production**
  - Inhibits gluconeogenesis
- **↑ insulin effects**
  - ↑ insulin sensitivity



Metformin

# Metformin

## Benefits and Adverse Effects


- Usually **first line in type 2 diabetes**
- Associated with **weight loss**
- Rarely causes hypoglycemia
- Does not depend on beta cells
- Can be used in advanced diabetes
- Most common adverse effect is **GI upset**
  - Nausea, abdominal pain
  - Can cause a metallic taste in the mouth



# Metformin

## Lactic Acidosis

- Rare, life-threatening adverse effect of metformin
- Exact mechanism unclear/controversial
- Metformin can increase conversion of glucose to lactate
- Beneficial for lowering glucose levels
- Too much → lactic acidosis
- Can be life threatening




Lactic Acid

# Metformin



## Lactic Acidosis

- Almost always occurs associated with other illness
- **Renal insufficiency**
- Liver disease or heavy alcohol use
- Acute heart failure
- Hypoxia
- Serious acute illness
- Metformin not used in patients with low GFR
- Often “held” when patients acutely ill
- Also held during IV contrast tests



# Sulfonylureas

- **↑ insulin release**
- Bind to sulfonylurea receptor in pancreas
- Close K<sup>+</sup> channels in beta cells
- Beta cells more sensitive to glucose/amino acids
- “Insulin secretagogues”
- Used when metformin contraindicated (renal failure)
- Or side effects on metformin (GI upset)
- Can be added to metformin



# Sulfonylureas

- Oral medications
- Each generation more potent
- ↓ dosage used → ↓ side effects
- First generation: tolbutamide, chlorpropamide, tolazamide
- Second generation: glyburide, glipizide
- Third generation: glimepiride



# Sulfonylureas

## Adverse Effects

- **Hypoglycemia**
  - Most common adverse effect
  - Sweating, palpitations
  - May occur with exercise or skipping meals
- Can also cause **weight gain**
  - More insulin release
  - Insulin causes weight gain



# Sulfonylureas

## Adverse Effects - Chlorpropamide


- **Flushing** with alcohol consumption
  - Inhibits acetaldehyde dehydrogenase (disulfiram effect)
- **Hyponatremia** (↑ADH activity)

1 H			
3 Li	4 Be		
11 Na	12 Mg		
19 K	20 Ca	21 Sc	22 Ti
37 Rb	38 Sr	39 Y	40 Zr

# Meglitinides

Repaglinide, Nateglinide

- Oral medications
- Similar mechanism but different chemical structure from sulfonylureas
- Close  $K^+$  channels  $\rightarrow$   $\uparrow$  insulin secretion
- Short acting  $\rightarrow$  given **prior to meals**
- Major side effect is hypoglycemia
- No sulfa group  $\rightarrow$  can be used in **sulfa allergy**
- Added to metformin if sulfa allergy



Repaglinide

# Thiazolidinediones

Pioglitazone, Rosiglitazone

- Oral medications
- **Decrease insulin resistance**
- Act on **PPAR- $\gamma$  receptors**
  - Highest levels in adipose tissue
  - Also found in muscle, liver, other tissues
  - Modulate expression of genes

# Thiazolidinediones

## Adverse Effects

- **Weight gain**
  - Proliferation of adipocytes plus fluid retention
- Risk of hepatotoxicity
  - Troglitazone removed from market due to liver failure
- **Edema**
  - Occurs in ~ 5% patients
  - Due to PPAR- $\gamma$  effects in nephron  $\rightarrow$   $\uparrow$  Na retention
  - Risk of pulmonary edema
  - Not used in patients with **advanced heart failure**
- Pioglitazone not used with active bladder cancer
  - Potential small increased risk of bladder cancer

Pulmonary Edema



# Glucosidase Inhibitors

Acarbose, Miglitol, Voglibose

- Competitive inhibitors of intestinal  **$\alpha$ -glucosidases**
  - Enzymes of brush border of intestinal cells
  - Hydrolyze starches, oligosaccharides, disaccharides
- Slows and limits absorption of glucose
- Taken orally before meals
- Less increase in glucose after meals
- Main side effect: GI upset
  - Especially **flatulence**
  - Diarrhea



# GLP-1 Analogs

Exenatide, Liraglutide, Dulaglutide

- **GLP-1 (glucagon-like peptide-1)**
  - Produced by L-cells of small intestine
  - Secreted after meals
  - Stimulates insulin release
  - Also blunts glucagon release, slows gastric emptying
- Subcutaneous drugs
- Exenatide: twice daily or weekly
- Liraglutide: once daily
- Dulaglutide: once weekly

# GLP-1 Analogs

Exenatide, Liraglutide, Dulaglutide

- Usually not used as initial therapy
- Add-on therapy in multi-drug regimens
- Do not usually cause hypoglycemia
- Associated with **weight loss**
- Reduce mortality in patients with **cardiovascular disease**
- GI side effects: nausea, vomiting, diarrhea



# DPP-4 Inhibitors

Sitagliptin, Linagliptin, Saxagliptin


- DPP-4: Dipeptidyl peptidase 4
  - Enzyme expressed on many cells
  - Inhibits release GLP-1
- Inhibition → ↑ **GLP-1**
- Oral drugs
- Side effects: **infections**
  - May depress immune function
  - ↑ risk nasopharyngitis and respiratory infections
- Weight neutral; not associated with hypoglycemia



# SGLT2 Inhibitors

Canagliflozin, Dapagliflozin


- SGLT2: renal glucose transporter
  - Expressed in proximal tubule
  - Reabsorbs sodium and glucose
  - Reabsorbs ~ 90% percent filtered glucose
- Inhibition → loss of glucose in urine
  - Lowers glucose levels
  - Also causes mild osmotic diuresis



# SGLT2 Inhibitors

Canagliflozin, Dapagliflozin

- Oral medications
- Lead to mild weight loss
- Adverse effects
  - **Vulvovaginal candidiasis**
  - **UTIs**
- May lead to volume depletion
- Not used **advanced renal disease (low GFR)**
- Shown to improve outcomes in **systolic heart failure**



# Diabetes Therapy

## Helpful Tips

- Renal failure: **avoid metformin**
  - May cause lactic acidosis
- Advanced heart failure
  - Avoid **glitazones** (fluid retention)
  - Avoid **metformin** (lactic acidosis)
- Insulin generally safe with any comorbidity
- Patients with cardiovascular disease
  - GLP-1 agonists (reduce mortality)
  - SGLT2 inhibitors (systolic heart failure)



# Diabetes Therapy

## Helpful Tips

- **Hospitalized patients**
  - Oral antidiabetic agents often held/avoided
  - Most patients treated with **insulin**
- Most oral agents decrease A1c by 0.5 to 1.5%
  - Metformin 1 to 1.5%
- Markedly elevated A1c % usually requires **insulin**
- Insulin used at diagnosis when Hgb A1c > 9.5%




# Pituitary Gland

Jason Ryan, MD, MPH




# Pituitary Gland

- “Master gland”
- Controls other endocrine organs
- Located at base of brain
- Sits in small cavity of sphenoid bone: sella turcica



# Pituitary Gland

- **Posterior pituitary**
  - Antidiuretic hormone (ADH; vasopressin)
  - Oxytocin
- **Anterior pituitary**
  - Adrenocorticotropic hormone (ACTH)
  - Follicle-stimulating hormone (FSH)
  - Luteinizing hormone (LH)
  - Growth hormone (GH)
  - Thyroid-stimulating hormone (TSH)
  - Prolactin




# Hypothalamus

- Controls anterior pituitary gland
- Delivers releasing/inhibiting hormones via hypothalamic portal system

Hypothalamus	Pituitary
Corticotropin-releasing hormone (CRH)	ACTH
Thyrotropin-releasing hormone (TRH)	TSH
Gonadotropin-releasing hormone (GnRH)	LH/FSH
Growth hormone-releasing hormone (GHRH)	GH
Dopamine	Prolactin
Somatostatin	GH, TSH

# Pituitary Adenomas

- Benign tumors of the **anterior pituitary**
- May produce hormones → hormone excess syndromes
- May compress nearby CNS structures → neurologic symptoms
- Classified by cell type of origin and size
- Microadenoma: < 10 mm in size
- Macroadenoma:  $\geq$  10 mm in size



# Pituitary Adenomas

## Cell types

Cell Type	Hormone	Adenoma
Lactotrophs	Prolactin	Hyperprolactinemia
Corticotrophs	Adrenocorticotrophic hormone (ACTH)	Cushing's disease
Thyrotrophs	Thyroid-stimulating hormone (TSH)	Central hyperthyroidism
Somatotrophs	Growth hormone (GH)	Acromegaly
Gonadotrophs	Luteinizing hormone (LH) Follicle-stimulating hormone (FSH)	Usually non-functioning

# Pituitary Adenomas

## Clinical presentation


- Most patients present with features of **hormone hypersecretion**
  - Hyperprolactinemia, hypercortisolism, growth hormone excess, etc.
- **Non-functioning adenomas:** about 30% of adenomas
  - Do not produce hormones
  - Usually gonadotroph adenomas
  - Usually identified as macroadenomas
  - Present with neurologic symptoms from mass effect
  - Or incidental finding on imaging
  - May grow large enough to cause hypopituitarism



# Pituitary Adenomas


## Mass effect symptoms

- Headaches
- Classic cause of **bitemporal hemianopsia**
- Compression of **optic chiasm**



# Prolactinoma

- Most common functional pituitary adenoma
- Excess pituitary production of **prolactin**
  - Normal: less than 20 ng/mL
  - Small prolactinoma < 1 cm: up to 200
  - Large prolactinoma over 2 cm: > 1000
- **Hypogonadism**
  - Prolactin → ↓ LH/FSH
  - Women: amenorrhea
  - Men: low testosterone
- Galactorrhea (uncommon)



# Hyperprolactinemia

## Clinical features and diagnosis

- Postmenopausal women: usually no symptoms from high prolactin
- Diagnosis: **serum prolactin level**


Premenopausal Women	Men
Oligomenorrhea Amenorrhea Infertility Decreased bone density Galactorrhea	Fatigue Loss of libido Decreased muscle mass Decreased body hair Infertility Galactorrhea*

\*less common due to less breast tissue

# Hyperprolactinemia

## Differential diagnosis


- Prolactinoma
- Dopamine-blocking drugs
  - **Antipsychotic drugs**
  - Usually mild and asymptomatic
  - Usually no treatment required



# Hyperprolactinemia

## Differential diagnosis


- Primary hypothyroidism
  - Increases TSH and TRH
- Chronic renal failure
  - Decreased clearance
- Hypothalamic disease
  - Tumors
  - Infiltrative disease (sarcoid)
  - Damage to pituitary stalk (trauma)
- Pregnancy or stress (physiologic)



# Hyperprolactinemia

## Workup


- History
  - Symptoms and medication review
- Exam
  - Visual field defects
  - Signs of hypothyroidism
- Lab testing
  - Thyroid: TSH
  - Renal: BUN/Cr
- **Pituitary MRI**



# Prolactinoma

## Management

- Small, asymptomatic adenomas → observation
- **Cabergoline or bromocriptine**
  - Treat symptoms of hyperprolactinemia
  - Hypogonadism or galactorrhea
  - Dopamine agonists
  - Will decrease prolactin release
- Transsphenoidal surgical resection
  - If medical management fails
  - Large adenomas with neurologic symptoms



Cabergoline


# Somatotroph Adenoma

- Causes **excess growth hormone**
- Children: gigantism
- Adults: acromegaly
- Growth hormone → **IGF-1 secretion**
  - Insulin-like growth factor 1
  - Secreted by liver
  - Causes many clinical manifestations

2 to 20 years: Boys  
Stature-for-age and Weight-for-age percentiles

NAME \_\_\_\_\_

RECORD # \_\_\_\_\_



# Acromegaly

## Clinical features


- Clinical syndrome of growth hormone excess
- Insidious onset
  - Average duration symptoms → diagnosis = 12 years
- **Enlarged jaw**
- Coarse facial features
- Enlargement of nose, frontal bones
- Enlarged **hands and feet**
  - Increasing glove or shoe size
  - Rings that no longer fit



# Acromegaly

## Insulin effects

- Growth hormone oppose insulin effects
- Insulin resistance → **diabetes**
  - Diabetes in 10-15% of patients
  - Abnormal glucose tolerance in 50% of patients



# Acromegaly


## Other clinical features

- **Visceral organ enlargement**
  - Thyroid, heart, liver, lungs, kidneys, prostate
- **Synovial tissue/cartilage enlargement**
  - Joint pain in knees, ankles, hips, spine
  - Common presenting complaint is joint pain
- **Cardiovascular disease**
  - Hypertension, left ventricular hypertrophy
  - Diastolic dysfunction and arrhythmias
  - Mortality increased in acromegaly due to CV disease

# Acromegaly

## Diagnosis


- **Serum IGF-1 concentration**
  - IGF-1 level is constant (contrast with GH)
- **Oral glucose tolerance testing**
  - Glucose should suppress growth hormone levels
  - Normal subjects: GH falls within two hours
  - Acromegaly: GH levels not suppressed
- CNS imaging (MRI)



# Acromegaly

## Treatment

- **Preferred treatment: surgery**
  - Medical therapy less effective
- Octreotide and lanreotide
  - Analog of somatostatin
  - Suppress somatotroph growth
  - Suppress release of growth hormone
- Monitoring: **IGF-1**
  - Goal level within reference range
- Bony abnormalities do not regress
- Joint symptoms often continue



# Pituitary Incidentaloma

## Common testing

- Prolactin
- Cortisol testing
- IGF-1
- TSH and free T4
- LH and FSH
- Testosterone (men)
- Estradiol (women)



# Hypopituitarism

- Decreased secretion of pituitary hormones

Hormone	Clinical Features
Adrenocorticotrophic hormone (ACTH)	Adrenal insufficiency
Thyroid-stimulating hormone (TSH)	Hypothyroidism
Luteinizing hormone (LH) Follicle-stimulating hormone (FSH)	Hypogonadism
Growth hormone (GH)	Short stature in children Adults: ↓ lean mass ↑ fat mass
Prolactin	Inability to lactate postpartum

# Hypopituitarism


## Diagnostic testing

Hormone	Testing
Adrenocorticotrophic hormone (ACTH)	Measuring serum cortisol
Thyroid-stimulating hormone (TSH)	Free T4 or total T4
Luteinizing hormone (LH) Follicle-stimulating hormone (FSH)	Testosterone (males) Estradiol (females)
Growth hormone (GH)	IGF-1
Prolactin	Levels variable

# Hypopituitarism

## Causes


- Hypothalamic disease
  - Tumors, trauma, stroke
- Pituitary disease
  - **Mass lesions** especially macroadenomas
- Radiation
  - Damage to hypothalamus or pituitary gland
- Pituitary infarction
- Pituitary apoplexy



# Pituitary Infarction

## Sheehan syndrome

- Ischemia and infarction of pituitary gland
- Occurs after **postpartum hemorrhage**
- Pituitary gland increases in size during pregnancy
  - Estrogen stimulates lactotrophs growth (prolactin)
- Postpartum hemorrhage/shock → infarction



# Pituitary Infarction

## Clinical features


- Variable based on degree of infarction
- Lethargy, anorexia and weight loss (cortisol, thyroid)
- Inability to lactate (prolactin)
- Failure to resume menses (LH/FSH)



# Pituitary Apoplexy

- Sudden **hemorrhage** into pituitary gland
- Most often into a pituitary adenoma
- Abrupt onset of severe headache, visual loss and diplopia
- Hypopituitarism: usually laboratory evidence only
- Diagnosis: head MRI or CT
- Treatment: surgical decompression of pituitary

Pituitary Apoplexy



Case courtesy of Assoc Prof Frank Gaillard, Radiopaedia.org, rID: 17664

# Hypopituitarism

## Treatment

Deficient Hormone	Treatment
Adrenocorticotrophic hormone (ACTH)	Glucocorticoids
Thyroid-stimulating hormone (TSH)	Levothyroxine
Luteinizing hormone (LH) Follicle-stimulating hormone (FSH)	Testosterone (males) Estrogens and progestins (females)
Growth hormone (GH)	Replacement in children Usually no replacement in adults
Prolactin	No replacement


# Hyperparathyroidism

Jason Ryan, MD, MPH



# Parathyroid Glands

- Four endocrine glands
- Located behind thyroid
- Secrete parathyroid hormone (PTH)
- Important for calcium and phosphate balance



# Parathyroid Hormone

## Net effects

- **↑ plasma  $\text{Ca}^{2+}$**
- ↓ plasma  $\text{PO}_4^{3-}$
- Some effects due to direct action PTH
- Some due to activation of vitamin D (indirect)

1  
H

3  
Li


11  
Na

19  
K

4  
Be

12  
Mg


20  
Ca



# Parathyroid Hormone

## Stimuli for secretion


- Major stimulus: ↓ **plasma Ca<sup>2+</sup>**
- ↑ plasma P<sub>04</sub><sup>3-</sup>
- ↓ 1,25-(OH)<sub>2</sub> vitamin D



# Parathyroid Hormone


## Systemic effects

- **Kidney**
  - $\uparrow$   $\text{Ca}^{2+}$  reabsorption (less urinary calcium)
  - $\downarrow$   $\text{P04}^{3-}$  reabsorption (more urinary phosphate)
  - $\uparrow$   $1,25\text{-(OH)}_2$  vitamin D production
- **GI tract**
  - $\uparrow$   $\text{Ca}^{2+}$  and  $\text{P04}^{3-}$  absorption (via vitamin D)
- **Bone**
  - $\uparrow$   $\text{Ca}^{2+}$  and  $\text{P04}^{3-}$  reabsorption (direct and via vitamin D)



# Hyperparathyroidism

- Excess release of PTH
- Primary: overactive glands
- Secondary: caused by hypocalcemia
- Tertiary: occurs in chronic kidney disease



# Primary Hyperparathyroidism

- Inappropriate secretion of PTH not due to low calcium
- **↑ PTH → ↑ Ca**
- Most common cause of outpatient **hypercalcemia**
  - Malignancy most common cause in hospitalized patients
- Most common in postmenopausal women
- Diagnosis: **serum calcium and PTH**
  - Must have hypercalcemia
  - PTH may be elevated
  - PTH may be inappropriately normal for high calcium

# Primary Hyperparathyroidism

## Causes

- Most common cause: adenoma (85% of cases)
- Hypertrophy of all four glands
- Multiple adenomas
- Rarely parathyroid carcinoma

Parathyroid Adenoma




# Primary Hyperparathyroidism

## Signs and symptoms

- Often incidental finding when asymptomatic
- **Recurrent kidney stones**
- “Stones, bones, groans, and psychiatric overtones”
  - Largely historical
  - Modern era, most patients diagnosed early


Kidney Stones



# Osteitis Fibrosa Cystica

- Classic bone disease of hyperparathyroidism
- Clinical features: bone pain and fractures
- **Subperiosteal bone resorption**
  - Commonly seen in bones of fingers
  - Irregular or indented edges to bones
- **Brown tumors (osteoclastoma)**
  - Appear as black spaces in bone on x ray

Brown Tumors



Brown Tumors



# Primary Hyperparathyroidism

## Diagnosis and workup

- Diagnosis: calcium and PTH
- **24-hour urinary calcium excretion**
  - May be high, normal or low
  - Not required for diagnosis
  - Used to estimate risk of renal complications
  - Elevated urinary calcium **excludes FHH**
- Familial Hypocalciuric Hypercalcemia
  - Disorder of *excess renal resorption* of calcium
  - Also causes hypercalcemia but low urinary calcium




# Primary Hyperparathyroidism

## Localization studies

- Used to identify hyperfunctioning tissue
- Done only if surgery being planned
- Not used for diagnosis
- **Sestamibi scintigraphy**
  - Technetium-99m-sestamibi (MIBI)
  - Concentrates in parathyroid glands
- Alternatives: ultrasound or CT-scan

Parathyroid MIBI Scan



# Primary Hyperparathyroidism

## Treatment

- Definitive treatment: **parathyroidectomy**
  - Pre-op nuclear imaging often done to identify hyperfunctioning tissue
  - Focused parathyroidectomy: remove adenoma only
  - Bilateral hyperplasia: remove 3.5 glands
  - Or remove 4 glands and implant tissue in arm
- Resolves symptoms of hypercalcemia (if present)
- Decreases risk of kidney stones
- Improves bone mineral density



# Primary Hyperparathyroidism

## Parathyroidectomy indications

- Indicated for **all symptomatic patients**
- Asymptomatic patients\*:
  - Age less than 50 years (lower surgical risk; more likely to progress)
  - Calcium more than 1.0 mg/dL above normal (~ 11.5 or higher)
  - Osteoporosis by DXA scan
  - GFR < 60 mL/min
- Many patients are older and asymptomatic
- Often do not require surgery

# Primary Hyperparathyroidism

## Parathyroidectomy complications

- Risks of recurrent laryngeal nerve damage
  - May result in hoarseness
- Post-op **hypocalcemia**
  - Remaining parathyroid glands may be suppressed
  - Numbness or tingling in fingertips, toes, hands
  - If severe: twitching or cramping of muscles
  - Treat with calcium supplementation



# Primary Hyperparathyroidism

## Medical therapy


- Used in poor surgical candidates with symptoms
- Bisphosphonates
- **Cinacalcet**
  - “Calcimimetic”
  - Activate calcium receptor in parathyroid glands
  - Inhibits PTH secretion




# Secondary Hyperparathyroidism

- Occurs in chronic kidney disease
- Chronically low serum calcium  $\rightarrow$   $\uparrow$  PTH
- No symptoms of hypercalcemia
- Results in **renal osteodystrophy**
  - Bone pain (predominant symptom)
  - Fractures (weak bones 2° chronic high PTH levels)
  - If severe, untreated can lead to osteitis fibrosa cystica

**$\uparrow$ PTH  $\downarrow$ Ca**




# Secondary Hyperparathyroidism



# Secondary Hyperparathyroidism


## Monitoring, treatment and prevention

- Standard monitoring in patients with low GFR
  - Calcium and phosphate
  - Vitamin D
  - PTH level
- Hyperphosphatemia: **phosphate binders**
  - Calcium-containing binders: calcium carbonate and acetate
  - Non-calcium-containing binders: sevelamer and lanthanum
- Treat vitamin D deficiency with supplementation
- Persistently elevated PTH: calcitriol



# Tertiary Hyperparathyroidism

- Consequence of **chronic kidney disease**
- Chronically low calcium → chronically ↑ PTH
- **Parathyroid hyperplasia**
- Parathyroid gland becomes autonomous
- VERY high PTH levels
- Calcium may become elevated
- Often requires **parathyroidectomy**



# FHH

## Familial Hypocalciuric Hypercalcemia

- Rare, autosomal dominant disorder
- **Abnormal calcium sensing**
  - Abnormal calcium sensing receptors (CaSRs)
  - Found in parathyroid glands and also kidneys
- Higher than normal set point for calcium
  - Normal PTH → ↑ calcium
- More renal resorption of calcium
  - Low urinary calcium



Smith KA, Ayon RJ, Tang H, Makino A, Yuan JX. Calcium-Sensing Receptor Regulates Cytosolic  $[Ca^{2+}]$  and Plays a Major Role in the Development of Pulmonary Hypertension. *Front Physiol.* 2016 Nov 4;7:517.

# FHH

## Clinical features

- Mildly elevated serum calcium
- Usually normal PTH
- **Low urinary calcium** (key finding!)
- Often looks like 1° hyperparathyroidism
- Real world distinction from 1° disease difficult
- Genetic testing available
- Usually does not require treatment




# PTHrP


## Parathyroid hormone-related protein

- Produced in many tissues
- Numerous normal effects
- Synthesized in large amounts by some **tumors**
  - Renal cell carcinoma, squamous cell lung cancer, others
- Leads to **hypercalcemia** of malignancy
- Increased calcium
- Low PTH
- Elevated serum PTHrP

Lung Cancer



# Hypercalcemia



# Hypoparathyroidism and Vitamin D


Jason Ryan, MD, MPH



# Hypoparathyroidism

- Inappropriately low PTH secretion
- Not due to hypercalcemia
- Causes **hypocalcemia**

**↓PTH      ↓Ca**



# Hypocalcemia

## Causes

- Hypoparathyroidism – low serum PTH
- Hypomagnesemia
  - Very low Mg inhibits PTH release
- High serum PTH – normal response to hypocalcemia
  - PTH unable to raise serum calcium
  - Vitamin D deficiency
  - Chronic kidney disease (↓ active vitamin D)
  - Resistance to PHT (pseudohypoparathyroidism)
- Key tests: Mg, PTH level, vitamin D, BUN/Cr

# PTH

# Hypocalcemia

## Signs and symptoms

- **Tetany**
- Muscle spasms
- Tingling of fingers, toes, around mouth
- Perioral numbness
- Trousseau's sign: hand spasm with BP cuff inflation
- Chvostek's sign: facial contraction with tapping on nerve
- Seizures
- Prolonged Qt interval

# Hypoparathyroidism

## Causes

- **Surgical excision**
  - Often accidental after thyroid or neck surgery
  - Common after parathyroid surgery
  - Post-op tingling, muscle spasms
- Autoimmune and genetic disorders
- Infiltrative diseases
  - Hemochromatosis, Wilson's
  - Metastatic cancer
- Radiation



# Hypoparathyroidism

## Management of hypocalcemia

- Goal: low normal serum calcium
- Normal range for total calcium: 8.5 to 10.0 mEq/L
- **Acute or highly symptomatic**
  - Tetany, seizures, prolonged Qt interval
  - Often post-op after thyroidectomy or other surgery
  - Intravenous calcium (calcium gluconate)
- **Chronic or minimal symptoms**
  - Oral calcium and vitamin D supplementation
  - Rare cases: recombinant human PTH (teriparatide)

# APS-I

## Autoimmune Polyglandular Syndrome Type 1


- Rare autosomal recessive disorder
- Mutations of **autoimmune regulator (AIRE) gene**
- Triad:
  - Mucocutaneous candidiasis
  - *Candida* infections of skin, nails, and mucous membranes
  - **Autoimmune hypoparathyroidism**
  - Adrenal insufficiency
- Hypoparathyroidism usually occurs **before age 10**
- Diagnosis: genetic testing

Oral Candidiasis



# DiGeorge Syndrome

- Immunodeficiency syndrome due to chromosomal **deletion at 22q11.2**
- Failure of 3<sup>rd</sup>/4<sup>th</sup> pharyngeal pouch to form
- Classic triad:
  - Loss of thymus (loss of T-cells, recurrent infections)
  - Loss of parathyroid glands (hypocalcemia, tetany)
  - Congenital heart defects
- Presents in infancy/childhood with:
  - Hypocalcemia (hypoparathyroidism)
  - Recurrent infections
  - Congenital heart disease




# Pseudohypoparathyroidism

## PHP

- Group of congenital disorders
- Kidney and bone unresponsiveness to PTH
- **PTH resistance**
  - Abnormal PTH receptor function (various subtypes)
- Usually presents in childhood
- **Hypocalcemia**
- **Hyperphosphatemia**
- Elevated PTH (appropriate)
- Normal vitamin D and renal function

## PTH Receptor



Thomas J. Gardella, and Jean-Pierre Vilardaga  
Pharmacol Rev 2015;67:310-337


# AHO

## Albright's Hereditary Osteodystrophy

- Type 1a form of pseudohypoparathyroidism
- Autosomal dominant GNA1 gene mutation
- Inability to produce cAMP after PTH binds receptor
- Hypocalcemia, hyperphosphatemia, ↑ PTH
- Collection of **clinical features**
  - Short stature
  - Shortened fourth and fifth metacarpals
  - Rounded facies
  - Mild intellectual impairment

# Vitamin D


- Raises serum calcium and phosphate
- Activated by **parathyroid hormone**
- Gastrointestinal tract:  $\uparrow$   $\text{Ca}^{2+}$  and  $\text{P04}^{3-}$  absorption
- Bone:  $\uparrow$   $\text{Ca}^{2+}$  and  $\text{P04}^{3-}$  resorption
- Deficiency: **hypocalcemia and hypophosphatemia**



# Vitamin D

## Forms


- Vitamin D<sub>2</sub> (ergocalciferol): found in plants
- Vitamin D<sub>3</sub> (cholecalciferol): found in fortified milk
- Skin synthesizes vitamin D<sub>3</sub>
- Requires **sunlight**
- Lack of sun exposure can lead to deficiency
- More common in winter months



# Vitamin D

## Activation

- Dietary or skin-produced vitamin must be activated
- Requires **hydroxylation** to become active
- Step 1: 25 hydroxylation - occurs in **liver**
  - Constant activity
- Step 2: 1 hydroxylation - occurs in **kidney**
  - Regulated by PTH




# Vitamin D

## Activated forms

- 25-OH Vitamin D: **calcidiol**
  - Produced by liver
  - Long half life
  - Storage form
  - Available for activation as needed
- 1,25-OH<sub>2</sub> Vitamin D: **calcitriol**
  - Produced by kidneys (proximal tubule)
  - Active form
  - Binds vitamin D receptors
  - Levels vary based on PTH
  - ↓ 1,25-OH<sub>2</sub> vitamin D in CKD → hypocalcemia

Nephron – Proximal Tubule



# Vitamin D

## Clinical importance of subtypes

- Determination of vitamin D status: **25-OH Vitamin D (calcidiol)**
  - Level of storage form
  - Level based on dietary intake and skin/sunlight
- Replacement in patients with no liver/kidney disease
  - Vitamin D3 (cholecalciferol)
  - Vitamin D2 (ergocalciferol)
- Replacement in advanced CKD: **1,25-OH<sub>2</sub> Vitamin D (calcitriol)**
  - Active form - restores vitamin D activity
  - Overcomes inability of kidneys to active vitamin D

# Vitamin D

## Deficiency

- Normal 25-OH vitamin D level: 20 to 40 ng/mL
- Deficiency: less than 20 ng/mL
- Most patients asymptomatic
- Elevated PTH level often maintains serum calcium
- Major adverse outcome is **bone disease**
- Severe cases: hypocalcemia

# Vitamin D Deficiency

## Bone disorders


- **Osteomalacia**

- Softening of bones
- $\downarrow$  vitamin D  $\rightarrow$  low calcium  $\rightarrow$   $\uparrow$  PTH  $\rightarrow$   $\downarrow$  bone mineralization
- Bone pain or tenderness
- Fractures

- **Rickets**

- Occurs in children
- Deficient mineralization of growth plate
- Bone pain
- Distal forearm/knee most affected (rapid growth)
- Bowing of femur/tibia (classic X-ray finding)

## Rickets




Michael L. Richardson, M.D./Wikipedia

# Vitamin D Deficiency

## Treatment

- **Cholecalciferol**
  - Vitamin D3
  - Used in patients with low 25-OH vitamin D
  - Improves vitamin D3 stores
  - Requires activation by kidneys
- **Calcitriol**
  - Active form of vitamin D3
  - Used in patients with renal disease and high PTH
- **Calcium supplementation**



# Vitamin D

## Screening

- Sometimes done in high-risk groups
- Limited sun exposure
- Institutionalized (nursing home residents)
- Osteoporosis
- Malabsorption




# Vitamin D

## Breast feeding

- Breast milk low in vitamin D
- Even if mother has sufficient levels
- Most infants get little sun exposure
- Exclusively breastfed infants → supplementation
  - 400 international units (drops)
  - Beginning a few days after birth



# Hypocalcemia



# Osteoporosis

Jason Ryan, MD, MPH



# Osteoporosis

- Porous bone
- Low bone mass and bone density
- Weak bones prone to fracture
- Usually no clinical symptoms until fracture



Normal bone



Osteoporosis

# Osteoporosis

## Diagnosis


- **Fragility fracture**
  - Fall from standing height or less
  - Not from major trauma (i.e. MVA)
  - Spine, hip, wrist, humerus, rib, or pelvis
  - Also a spontaneous vertebral “compression” fracture
- **T score of -2.5 or lower**



# DXA


## Dual-energy X-ray absorptiometry

- Two X-rays of different energy levels aimed at bones
- **T score**
  - Patient BMD vs. healthy 30-year-old BMD
  - Normal: -1.0 or higher (least fractures)
  - Osteopenia: -1.0 to -2.5
  - Osteoporosis: -2.5 or lower (most fractures)
- **Screening in women**
  - Every 3 to 5 years
  - All women  $\geq 65$  years old
  - Women  $< 65$  with risk factors
- Screening not recommended in men



# Bone Mass

- Peak bone mass occurs in young adulthood
  - Many influences: sex, genetics, diet
- Decreases slowly thereafter
  - Each resorption/formation cycle → some bone loss
- Males achieve higher peak bone mass
- Menopause accelerates bone loss
  - Caused by decreased estrogen levels
- Female osteoporosis >> male osteoporosis
- Weight-bearing activity → ↑ bone mass



# Osteoporosis

## Selected Risk Factors

- **Alcohol**
  - Heavy use associated with osteoporosis
  - Moderate use effects not clear
- **Smoking**
  - Accelerates bone loss
- Low body weight (< 127 lbs)
- Advanced age



# Osteoporosis

## Subtypes


- **Primary osteoporosis**
  - Most common form
  - Postmenopausal osteoporosis (type I) – estrogen deficiency
  - Senile osteoporosis (type II) – age-related bone loss (men and women)
- **Secondary osteoporosis**
  - Not related to menopause or aging
  - Suspected in pre-menopausal women
  - Caused by drugs or another medical disorder



# Secondary Osteoporosis

## Glucocorticoids


- Affect osteoblasts and osteoclasts
- Increase bone resorption
- Reduce bone formation



# Secondary Osteoporosis

## Antiepileptic Drugs


- Phenobarbital, Phenytoin, Carbamazepine
- Used to treat seizures and epilepsy
- Risk of osteoporosis with long term therapy
- Increase activity of P450 enzymes
- Increases breakdown of vitamin D
- Less calcium → increased PTH → bone loss



# Secondary Osteoporosis

## Unfractionated Heparin

- Only with long term use
- Decreases bone formation
- Increases resorption
- Low molecular weight heparin: unclear bone effects



Unfractionated Heparin

# Secondary Osteoporosis

## Endocrine disorders

- Cushing's syndrome or disease ( $\uparrow$  cortisol)
- Hyperthyroidism
- Hyperparathyroidism
- Hypogonadism ( $\downarrow$  estrogen)

Cushing's Syndrome



# Secondary Osteoporosis

## Endocrine Disorders

- Cushing's syndrome or disease ( $\uparrow$  cortisol)
- Hyperthyroidism
- Hyperparathyroidism
- Hypogonadism ( $\downarrow$  estrogen)


Cushing's Syndrome



# Secondary Osteoporosis

## Nutritional Associations

- Vitamin D deficiency
- Calcium deficiency
- Malabsorption (celiac disease)



# Secondary Osteoporosis

## Selected Testing

- Suspected in premenopausal women
- History and physical exam may be used to guide testing

Disorder	Testing
Celiac Disease	CBC (anemia)
Calcium deficiency	Serum calcium
Vitamin D deficiency	25-hydroxyvitamin D
Hyperthyroidism	TSH
Hyperparathyroidism	Calcium, phosphate +/- PTH
Chronic renal/liver disease	Creatinine and LFTs

# Osteoporosis

## Treatment

- **Lifestyle modification**
- Weight-bearing exercise
  - Exercise while standing and bearing body weight
  - Walking, hiking, jogging, playing tennis, etc.
  - Not swimming, cycling, rowing
- Avoidance of heavy alcohol use
- Smoking cessation
- Calcium and vitamin D supplementation
  - Calcium 1200 mg daily
  - Vitamin D 800 international units daily








# Bisphosphonates

Alendronate, Risedronate, Zoledronate, Ibandronate

- First line medical therapy
- Analogs of pyrophosphate
- Two phosphonate ( $\text{PO}_3$ ) groups attached to carbon
- Vary by side chains (R1 and R2)
- **Inhibit osteoclasts**
- Oral and IV drugs

Bisphosphonate



Agent	R <sub>1</sub> side chain	R <sub>2</sub> side chain
Etidronate	-OH	-CH <sub>3</sub>
Clodronate	-Cl	-Cl
Tiludronate	-H	-S- 
Pamidronate	-OH	-CH <sub>2</sub> -CH <sub>2</sub> -NH <sub>2</sub>
Neridronate	-OH	-(CH <sub>2</sub> ) <sub>5</sub> -NH <sub>2</sub>
Olpadronate	-OH	-(CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>
Alendronate	-OH	-(CH <sub>2</sub> ) <sub>3</sub> -NH <sub>2</sub>
Ibandronate	-OH	-CH <sub>2</sub> -CH <sub>2</sub> N 
Risedronate	-OH	
Zoledronate	-OH	

# Bisphosphonates

## Common adverse effects

- Oral drugs: alendronate and risedronate
- **Upper GI upset**
- Reflux, esophagitis, esophageal ulcers
- Local effects of bisphosphonates on mucosa
- Not used in patients with esophageal disease
- Often taken weekly
- Take with water on empty stomach
- Remain upright for 30 minutes



# Bisphosphonates

## Common adverse effects


- IV drugs: zoledronate and ibandronate
- Flu-like symptoms
- 24 to 72 hours after infusion
- Low-grade fever, myalgias
- Treated with ibuprofen and acetaminophen
- Long dosing intervals: 3-months to annually



# Bisphosphonates

Rare, serious adverse effects

- **Atypical femur fractures**
  - Below lesser trochanter
  - No or minimal trauma
  - Usually occur after 5 years of therapy
- **Osteonecrosis of the jaw**
  - Pain, swelling of mandible
  - May lead to exposed bone, local infection
  - May cause pathologic fracture of jaw
  - Often occurs in patients with cancer




# Bisphosphonates

## Other Indications

- **Hypercalcemia**
  - ↓ bone resorption → ↓ serum calcium
- **Paget's disease of bone**
- **Metastatic bone disease**
  - Improve outcomes
  - ↓ pathologic fractures and spinal cord compression
  - ↓ hypercalcemia of malignancy
  - ↓ need for radiation or bone surgery

Spinal Bone Mets MRI




# Osteoporosis

## Other Treatments

- Used in patients who cannot take bisphosphonates
- Or who do not respond to bisphosphonates
- Teriparatide
- Raloxifene
- Calcitonin
- Denosumab

# Teriparatide

- Recombinant **human parathyroid hormone (PTH)**
- Continuous administration of PTH
  - Bone resorption → ↑ serum calcium
  - Important physiologically
- Low dose once daily bolus administration
  - Increased bone mass
  - Increased osteoblast bone formation
- Teriparatide: subcutaneous daily injection




# Teriparatide

## Adverse Events

- Generally well tolerated
- May cause nausea or dizziness
- **Transient hypercalcemia**
  - Brief rise in serum calcium
  - Drug has quick on/off effect over hours
  - Rarely leads to very high levels or symptoms
  - Levels return to baseline within four hours


1 H	
3 Li	4 Be
11 Na	12 Mg
19 K	20 Ca



# Raloxifene

SERM (Selective Estrogen Receptor Modulator)

- Estrogen actions on bone
- Anti-estrogen in breast
- Reduces risk of breast cancer
- May cause **hot flashes**
- Associated with **DVT/PE**
- Minimal effects on uterus
- Not associated with bleeding, hyperplasia/cancer



Raloxifene

# Calcitonin

- Hormone produced by thyroid
- Binds to osteoclasts
- Inhibits bone resorption
- Salmon calcitonin used for osteoporosis
- Second-line therapy
- Intranasal administration
- May cause hypocalcemia
- May cause rhinitis



# Denosumab

- Monoclonal RANK-L antibody
- Blocks osteoblast activation of osteoclasts
- Given subcutaneously every six months
- Usually well-tolerated with few adverse effects

